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Abstract
Lung cancer (LC) is leading in the number of deaths among the other types of cancer.
According to the American Cancer Society, 135,720 deaths during 2020 in the USA will be
associated with LC. The patient 5-year survival rate of 16% was reported in 1986 and 19%
in 2019. One of the reasons why survival rate remains low is that the majority of patients
diagnosed with cancer had stages III and IV. In contrast, a 5-year survival rate of 70% was
reported for patients of stage IA after surgical resection in the National Lung Screening
Trial.
CT screening detects a number of pulmonary nodules that have to be classified as benign
or malignant. Radiomics is based on the concept that quantitative features extracted from
medical images can be effectively used for differentiation of abnormal tissue into benign or
malignant categories by applying machine learning methods. Such computer-aided decision
making (CAD) systems were shown to be effective tools for patient diagnosis, treatment
response prediction, cancer aggressiveness estimation, and gene mutation type detection.
Conventional radiomic features describe the size, shape, location, and structural patterns
(texture) of tissue. Texture features are commonly computed over the entire nodules and
thus they are averaged with respect to different texture patterns presented in a nodule. In
comparison, a set of algorithms is focused on the detection of nodule subregions with similar
properties (habitats), such as texture, as a part of the feature extraction step, and used
information about habitats to describe a nodule.
This dissertation introduces new algorithms designed to increase the performance of
patient diagnostic systems as well as lung cancer tumor’s aggressiveness categorization. Di-

viii

agnosis experiments were performed on the National Lung Screening Trial (NLST) dataset.
Cancer aggressiveness estimation experiments were performed on a set of patients diagnosed
with Adenocarcinoma at the H. Lee. Moffitt Cancer Center & Research Institute. Due to
the variance of reported nodule sizes, the dataset was split into size categories and each CAD
system for a size-group was designed individually. As an extension for the size split project,
delta features were computed and added into the feature set. Delta features characterize
temporal changes in a nodule. A lung cancer diagnosis system that utilizes baseline and
delta features is reported. A novel habitat revealing algorithm was presented and its utilization for lung cancer diagnosis and lung cancer aggressiveness classification is provided in
detail. Considering the beneficial usage of the developed approaches as a set of independent
methods, a delta habitat revealing algorithm was designed. The delta habitat revealing algorithms quantify information about habitats within a nodule and how these habitats changed
in time. The performance evaluation was performed using the NLST dataset, thus a split of
patients into size-groups was performed. Finally, we designed several experiments to show
that size is an important feature not only in clinical practice and Radiomics but also for
Convolution Neural Networks that process only image data. If warping (up-sampling) was
applied as a pre-processing step, it is shown that the size of a nodule is encoded in texture
and decoded by CNN for decision making.
Nodule classification Area Under Receiver Operating Curve (AUROC) in the NLST
dataset was improved from 0.69 to 0.79 by developing CAD systems for nodule size-groups
independently. The inclusion of delta features enhanced CAD classification AUROC to 0.86
in the NLST. Features that were produced by the habitat revealing algorithm statistically
significantly improved lung cancer patient survival time classification AUROC from 0.71 to
0.91 in a set of adenocarcinoma patients. Finally, AUROCs of 0.91, 0.87 and 0.92 were
achieved for “small”, “medium” and “large” size-groups in the NLST dataset by combining
delta-habitat and conventional radiomic feature sets. A CNN model trained from scratch

ix

to differentiate ”small”/”large” nodules and a CNN model, that originally was trained to
classify cancer/non-cancer nodules, tuned to classify size categories showed accuracy more
that 80% and AUROC more than 0.80 for a variety ”small”/”large” labeling methods.
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Chapter 1: Introduction

Cancer is a disease in which abnormal cells divide without control. The uncontrolled
cell population growth caused by a mutation originally occurring in a normal cell (driver
mutation). Due to a constant cell division process, abnormal tissue accumulates additional
somatic mutations. With a new mutation, a new population of cells appear. As a result,
the accumulation of mutations defines one of the main cancer properties: heterogeneity.
Populations of cells with different mutations have different sets of observable cell characteristics (phenotypes) resulting from the interaction of their genotypes with the environment.
An individual cell population with similar phenotypes is called a habitat. Heterogeneity
is information about habitats within a tumor or a nodule Figure 1.1 shows a schematic
presentation of the mutation collection process within an abnormal mass in pancreatic carcinogenesis. At each iteration, cells with the same color can be considered habitats. The
presence of different habitats within a nodule at each given time-point can be considered to
show the heterogeneity of a nodule at that time.
Medical examination devices, such as Magnetic Resonance Imaging (MRI), Positron
Emission Tomography (PET), and Computed Tomography (CT) scanners, provide biological
information about the patient’s tissue in a non-invasive way. This information is presented
as a set of digital images (Imaging Sequence). Digital representation allows quantification
of information in terms of tissue attributes as well as the measurement of similarities and
differences between patients. Some of these attributes can be found by a clinician in a visual
examination of the image data without any assistance. For example, nodule size, shape, loca-

1

Figure 1.1: Clonal evolution of pancreatic carcinogenesis and progression. Red arrows
indicate the lineage of the index metastasis from its origin in a normal cell. Carcinogenesis,
and time T1, begins with an initiating alteration (M) in a normal cell that provides a
selective advantage. Over time, waves of clonal expansion occur in association with the
acquisition of additional mutations in genes such as CDKN2A, TP53 or SMAD4,
corresponding to the progression model of PanIN. This clonal expansion is expected to
generate more than one subclone within a PanIN, one of which will give rise to the founder
cell (blue clone) that will eventually become the parental clone and hence initiate the
infiltrating carcinoma. The birth of this cell corresponds to the beginning of time T2.
Following additional waves of clonal expansion from the parental clone, subclones are again
generated within the infiltrating carcinoma leading to genetic heterogeneity. The birth of
the cell within the primary carcinoma that will become the metastatic subclone (green
clone) corresponds to the start of time T3. Whether a single metastatic subclone generates
all metastases in a patient is currently unknown. This figure is adapted from Yachida S. et
al [1].
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tion, and solidity can be captured from a CT image [2]. After clinical trials these attributes
became standard patient risk-score metrics [3]. In addition, to eye-detectable attributes
medical image processing provides tools to mine a large number of advanced cancer features
that are impossible to compute manually. That led to the appearance of Radiomics [4].
Radiomics is the process of converting standard of care digital medical images into quantitative image based feature data that can be subsequently analyzed using conventional
biostatistics and machine learning methods [4]. With high throughput computing, it is now
possible to rapidly extract radiomic features from a region of interest where the features
quantify its size, shape, intensity, and texture. As radiomic features are likely capturing
biological and pathophysiological information of the region of interest [4], radiomics has the
potential to provide a rapid and accurate noninvasive approach to better manage pulmonary
nodules detected by Low-Dose Computed Tomography (LDCT) in the lung cancer screening
setting as well as by Contrast-Enhanced Computed Tomography (CECT) in pre-treatment
imaging.
In Radiomics heterogeneity is important. It affects a patient’s diagnosis and treatment.
Chapter 2 provides an overview of quantitative features that are used in the literature to
describe heterogeneity. Due to high variability in cancer, there are several principles in Radiomics that serve to increase research quality and improve model performance. 1) Compare
things that can reasonably be compared i.e. patients with the same driver mutation are
used for a treatment response prediction model design rather than mixing all the patients
in a single dataset. 2) Divide and conquer. Different habitats of a nodule may have different properties i.e. some habitats of a nodule can be drug-sensitive and at the same time,
other habitats can be drug-resistant. Analyze habitat properties. 3) The more information
known the better. Radiomics uses image-based features, but the same patient may have
multiple sequences performed at multiple time-points. Changes in a nodule can represent
the dynamics of cancer and can be used for patient differentiation.
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The risk that an indeterminate pulmonary nodule (IPN) is malignant is directly correlated
with the size of a nodule. The larger the nodule the higher the risk that a patient has
cancer [3]. At the same time, the size of the nodule reported in the National Lung Screening
Trial (NLST) dataset varies from a couple of millimeters to several dozen millimeters. As
recommended by the National Comprehensive Cancer Network (NCCN) [5] and the American
College of Radiology (ACR) [4,6], the current cutoff size for assessing lung nodules increased
to 6 mm rather than the 4 mm originally used in the NLST [7, 8]. Although this increase
in threshold positivity has been reported to decrease false-positive results [3, 6, 9], decision
support tools and lung cancer risk prediction are still lacking for IPNs ≥6 mm. Following the
assumption that nodules in different size-groups may have different predictive biomarkers,
size-specific classification models were designed for IPN diagnosis. In Chapter 4, a size-guided
lung nodule diagnostic workflow and the performance of models are presented.
The fact that a nodule was classified as a benign nodule at the baseline screen does not
guarantee that in time the nodule will not evolve into a malignant tumor. Radiomic features
that characterize size, location, and texture represent a condition of abnormal tissue at the
time-point when imaging was performed. In clinical practice patients that are reported as
nodule positive may have follow-up screens. Differences between features extracted from the
baseline and the follow-up screens (delta features) represent the dynamics of cancer [10–12].
As an extension to the project, size-specific classification models were designed using a feature
set augmented with delta features. Chapter 4 results show that delta features improve lung
cancer nodule diagnostic performance.
Features that characterize abnormal tissue within the entire region of interest (ROI)
average properties of the habitats [13]. For example, if half of a nodule is solid and half
of a nodule has a ground-glass opacity (GGO) then the computation of mean intensity will
represent tissue density that may not have even occurred in a nodule. Spatial heterogeneity
analysis focuses on the detection of nodule habitats and uses information about habitats and
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their properties for patient differentiation. Chapter 5 describes an algorithm that detects
habitats in IPNs and pre-treatment imaged tumors. Features extracted from habitat maps
improved lung cancer diagnosis as well as for adenocarcinoma, lung cancer aggressiveness
estimation.
Each diagnostic method described above, split IPNs into size groups, using a feature
set with delta features, and habitat features, shows improved nodule diagnosis performance.
Chapter 6 states an extension of the habitat revealing algorithm such that habitats are
detected in multi time-point CTs. Features extracted at both time points are used to compute
delta features. IPN diagnostic model design was done for each size-group independently. The
algorithm combines principles that were used in previous methods.
Nodule size is one of the most significant and well-studied characteristics of lung cancer
potential. Lung-RADS guideline uses nodule longest diameter for lung cancer risk-score
computation in CT screens [14]. Chapters 4, 6 describe size-based algorithms for lung cancer
diagnosis. Overall, the size of a nodule is one of the most robust predictors in Radiomic
studies. At the same time, Convolutional Neural Networks (CNN) were shown to produce
high accuracy in cancer diagnosis using imaging data only [15–17]. One of the image preprocessing methods is warping where the minimum enclosing bounding box for nodule ROI is
used to extract an image patch and then the patch is up-sampled to an image with resolution
equal to the CNN input image resolution [18]. Chapter 7 provides experimental evidence
that up-sampling encodes size information into image texture and a CNN model is capable
of decoding size information from an image as well as use it for its decision making.
In Chapter 8 advantages, limitations and future projects are discussed.
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Chapter 2: Literature Overview

This chapter is focused on image processing methods that have been introduced to reveal
intramural, peritumoral, and spatial heterogeneity. Experimental design details, project
motivation, imaging modalities, and model performance are shown in the appendix. The
following sections provide details of appendix table numbers that present the discussed works
in detail.
There are several review papers in the literature. Winfield et al. [19] are focused on
MRI technical challenges in data acquisition, data analysis, and data interpretation. The
authors overview the performance of Radiomics models in Gliomas, Prostate and Breast
cancers. Napel et al. [20] focus on habitat detection using multiparametric MRI (mpMRI)
and PET/MRI imaging with a description of the biological properties of habitats. Goto et
al. [21] describe tumor heterogeneity and evaluation from genetic processes. The authors discuss new potential personal treatment approaches. Thawani et al. [22] and Crivelli et al. [23]
focus on Radiomics models in Lung Cancer and Breast Cancer respectively. Sala et al. [24]
overviewed Radiomics methods and the relation of medical imaging and Radiogenomics.
Chicklore et al. [25] overviews heterogeneity methods in

2.1

18

F-FDG PET imaging.

Imaging Modalities
Computed Tomography uses radiation emissions for imaging [26, 27]. For each voxel,

tissue radiation absorption is defined. The higher the absorption, the higher the resulting
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voxel value. Because tissue radiation absorption is highly correlated with tissue density it is
possible to say that CT provides information about tissue density.
Positron Emission Tomography uses radioactive contrast for visualization [28, 29], For
example,

18

F-fluorodeoxyglucose (18 F-FDG).

glucose as nutrition. Thus, the

18

18

F-FDG concentrates in the tissue which uses

F-FDG PET result is associated with metabolic activity.

Voxel intensity is measured in Standard Uptake Values (SUV) quantified by patient size and
injected contrast dose [30].
Magnetic Resonance Imaging estimates the response of the atomic nuclei of body tissues
to high-frequency radio waves when placed in a strong magnetic field [31–35]. MRI can
produce multiple image sequences based on predefined settings. For example, T1 , T2 , Fluidattenuated inversion recovery (FLAIR), Dynamic Contrast Enhanced MRI (DCE-MRI), etc.
Due to the large number of possible parameters in MRI and the complexity of image visualization methods they are not described in this work.
Lung movement associated with breathing as well as the heart beating makes MRI imaging a practically impossible type of imaging for lung cancer studies. In comparison, MRI
and PET modalities are favored in brain and breast cancer due to informativity, low risk for
a patient (MRI), and the high level of biological interpretation.
CT and PET use radiation for imaging. Thus, these methods have a non-zero risk related
to a radiation dose to patients and can’t be performed widely and often. On the other hand,
MRI uses a strong magnetic field and does not expose the patient to the effects of radiation.
Nevertheless, it cannot be used for imaging patients who have any kind of metallic implants.

2.2

Intratumoral Heterogeneity
Cancer is known to be heterogeneous. A tumor may have different observable properties

(phenotypes). Here is an example list of some phenotypes which can be used for quantitative cancer description: metabolic activity, oxygenation, growth speed, drug resistance, cell
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density, tissue organization, and blood flow. Radiomics uses various types of features e.g.
size, shape, location, and texture to describe phenotypes. A combination of these features is
used to build a radiomic model. Some of these features capture the consistency of an image
within a VOI. For example, texture measures the spatial structure of an image. Such features
are associated with intratumoral heterogeneity. In this paper heterogeneity is defined as a
measurement of difference for a given phenotype within tissue.
After imaging, the location of abnormal tissue masses is detected manually or using a
(semi)automated algorithm by defining a VOI. Segmentation and source images are used for
feature extraction. In this section there is an overview of image processing methods used in
the literature to evaluate intratumoral heterogeneity.

2.2.1 First Order Statistics
Cancerous processes in tissue are highly associated with metabolic activity.

18

F-FDG

PET imaging can show areas where the contrast accumulates in tissue, which uses glucose
as nutrition. In this case, mean and maximum SUV values correlate with malignancy and
aggressiveness of tissue and are used as a biomarker for patient survival time prediction and
patient treatment response.
Similarly, Diffusion-Weighted Image (DWI)-MRI measures water molecule movement.
Results of DWI-MRI are used to compute the Apparent Diffusion Coefficient (ADC). Low
ADC values are associated with solid tumors. High ADC values are associated with necrosis
and edema. The presence of necrosis and edema are used as biomarkers of poor treatment
response.
SUV first-order statistics have been shown to be a predictive biomarker for breast cancer
patient survival time [36]. SUV first-order statistics are shown to be associated with clinical
response to treatment in breast cancer [37]. The minimum of the ADC value was shown to
be a statistically significant diagnostic feature in breast cancer [38].

8

In breast cancer xenograft model analysis has been performed on ADC maps for necrosis
detection [39].

18

F-FES and

18

F-FDG PET sequences are used for the estrogen receptor’s

status definition [40].
Detailed information about the performance reported in the work referred in this sections’
papers are described in Appendix Table B.1.

2.2.2 Second-Order Statistics
As an extension of previous works entropy and variance are used as biomarkers. From CT
scans second-order statistics can be associated with the semantic features tumor spiculation
and lobulation. For example, in lung cancer, a lower entropy value implies a solid nodule
and higher entropy indicates a higher order of spiculation of the tumor.
In lung cancer, second-order statistics from CT scans have been shown to be a predictive
biomarker of the presence of nodal metastasis [41].
In breast cancer, MRI entropy has been shown to be highly correlated with histopathology
findings [42]. T1 and T2 entropies were shown to be statistically significant predictors of
patient survival [43].
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table B.2.

2.2.3 Texture
First and second-order statistics measure intensity characteristics across an entire VOI.
They have clear clinical interpretation, but the disadvantage of these approaches is that they
ignore spatial information. In comparison, texture features measure the spatial structure of
voxel intensities.
Images can be convolved with a predefined kernel, where a kernel is characterized by a set
of weights. Each voxel from a VOI, its value, and N neighboring values, where N depends on
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the size of the kernel, are multiplied with the corresponding weight from the kernel. Results
of multiplication are summed up and produce a convolution value. A high convolution value
shows high spatial concordance between a given kernel and voxel neighbors. The set of
convolution values for each voxel within a VOI is called a convolution map. The sum of all
convolution values in a VOI is called a convolution feature for a given kernel. Law’s [44],
Wavelet [45] and Laplacian of Gaussian [46] (LoG) texture features are based on that type
of computation.
Gray Level Cooccurrence Matrix (GLCM) features use a cooccurrence matrix as a basis
for feature computation. A cooccurrence matrix has the same number of rows and columns as
the number of unique intensity values in an image. Each image intensity value is associated
with a unique index of rows and columns in a cooccurrence matrix. A probed voxel’s intensity
value is used as an index in a matrix and thus it defines a row in the cooccurrence matrix, its
left neighbor’s intensity value defines a column in the cooccurrence matrix. The particular
cell value is incremented. The process repeated for each voxel in a VOI. The resulting
cooccurrence matrix is used for computation of multiple statistical features e.g. entropy of
a GLCM. At that point, there is a fundamental difference between GLCM and convolution
features. Convolution uses raw data as well as a predefined kernel and GLCM computes a
set of features from the cooccurrence matrix for which construction and computation can be
interpreted as a preprocessing step.
There are multiple types of texture features that have been developed in the image
processing field. For example Run-Length, Ridz, Fractals, Gabor, etc. They have different
computational concepts as well as interpretation. Their detailed description can be found
in specialized textbooks [47, 48]. Nevertheless, all of them can be used in medical imaging
analysis.
Cooccurrence matrix features have been shown to have a high Spearman rank coefficient
with metabolically active tumor volumes as well as prognostic value in multiple types of
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cancer [49]. In breast cancer, GLCM features are associated with treatment response [37].
Clustering of texture features from PET/CT split patients into groups with different therapy
response in breast cancer [50]. Texture features were shown to be representative of mutation
status [51]. Local recurrence after radiotherapy in early lung cancer stages can be predicted
with GLCM features [52].
Lung cancer tumor segmentation variance across PET/CT modalities has been shown to
be correlated with cooccurrence matrix entropy [53]. Association of contrast-enhanced CT
texture features with pathological grade was analyzed in [54]. Fractal features from PET
images were differential biomarkers for benign and malignant nodules [55].
In brain cancer, T1 MRI GLCM features were shown to be highly predictive in long/short
time survival patient classification [56] as well as texture features from multi-sequence
MRI [57]. Texture features from multiple MRI sequences have been used for glioma subtype
differentiation [58].
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table B.3.

2.2.4 Filtering and N-Order Statistics
As mentioned above, high convolution values show a high local spatial concordance between the given kernel structure and voxel neighbors. Thus, convolution can be used as
a filtering method for detecting image regions where the voxel spatial structure matches a
given kernel structure. In addition, an image can be filtered by convolution with statistical
filters. Results of that type of convolution come from local statistical feature computations
e.g. an entropy value computed out of a given voxel and its neighbors.
First and second-order statistical features can be computed on filtered images.
In a lung cancer study, Ganeshan et al. [59] used a Laplacian of Gaussian (LoG) convolution kernel to detect areas with extensive voxel intensity changes. Convolution of a
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Laplacian of Gaussian kernel with an image is equivalent to image derivative computation.
The authors computed the entropy of the filtered CT images and showed that entropy can
be used as a biomarker for overall patient survival.
In breast cancer, Parekh et al. [60] showed a statistical difference between values in
mpMRI entropy convolution maps for benign and malignant nodules.
In brain cancer, LoG filtering followed by computation of second-order statistics computation was shown to be a robust approach for patient survival time prediction [61].
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table B.4.

2.2.5 Filtering and Texture
As an extension of filtered image analysis, texture features can also be computed on
filtered images.
Prasanna [62] suggests filtering an image by computation of gradient vectors for all voxels
within a VOI. After gradient vector discretization, a cooccurrence matrix is computed by a
comparison of neighboring gradient vectors. The authors evaluated the performance of the
method on three datasets: Brain, Breast, and Lung cancers.
A filtering approach was used in the PyRadiomics feature extraction package [63]. After
extraction of texture features from an image, a texture filter was applied and the resulting
filtered image was used for texture features computation.
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table B.5.

2.3

Peritumoral Heterogeneity
Abnormal tissue boundary definition is an object of multiple studies. In many cases,

it can be hard to differentiate a tumor edge using images. For example, FLAIR and T1
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MRI sequences may depict two totally different areas that are associated with cancer. The
tissue surrounding the abnormal mass can be affected by cancerous processes. Following
the assumption that the influence can be measured and employed in Radiomics, researchers
examined peritumoral heterogeneity.
Multiple types of tissues can be targeted in Peritumoral Heterogeneity computation.
Peritumoral tissue is considered normal and surrounds an abnormal mass. Border tissue is
tissue which considered to be an abnormal mass and ”close” to normal tissue. Abnormal
tissue core is tissue that is ”far” from normal tissue. Quantitative measurements for ”close”
and ”far” terms are determined by authors.
Segmentation of the targeted types of tissue can be performed manually [64] as well
as semi-automatically [65] and in the case when the tumor VOI is known, peritumoral,
border and core regions can be defined with erosion and dilation operators [66]. After the
segmentation step is performed, features used in intratumoral heterogeneity evaluation can
be extracted from the defined regions and analyzed.
In lung cancer, radial features extracted from the peritumoral area predict adenocarcinoma patient survival time [67]. An entropy map for tumor core and boundary in Adenocarcinoma Lung Cancer CT sequences has been used for patient survival time prediction [68].
First and second-order statistical features, as well as GLCM features, were extracted from
the peritumoral area and shown to have diagnostic information [69]. The maximum CT
value and the Size Zone Variance feature were shown to be statistically significantly correlated with adenocarcinoma patient survival time [70]. Differences between core and border
texture features showed a statistically significant difference in benign and malignant nodules [66].
In breast cancer, the combination of peritumoral and intratumoral DCE-MRI texture features was predictive in treatment response [71]. Wang et al. [65] used gray-level thresholding
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with manual correction of the segmentation for peritumoral tissue definition. Extracted
texture features were used for triple-negative breast cancer identification.
In brain cancer, Skogen et al. [64] defined peritumoral edema as the hyperintense region
on FLAIR sequences within 1cm of the tumor. The VOI was manually drawn. Authors used
the LoG operator as a filter and after filtering extracted first and second-order statistics as
features for differentiation of glioblastoma from brain metastasis.
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table C.1.

2.4

Spatial Heterogeneity
The concept of Intratumoral Heterogeneity evaluation, the usage of the entire VOI, gen-

erally averages phenotypes with a tumor [72]. In comparison, Spatial Heterogeneity studies
address two questions: 1) How a VOI can be differentiated into sets of subregions (Habitats)
with unique phenotypes? 2) What are the roles of revealed habitats in Oncology? A habitat
is defined as a subset of a tumor, where the difference among its subregions is less than a
predefined threshold for a given phenotype. In this section, imaging methods used in the
literature to split a VOI into habitats are described.

2.4.1 Multiparametric MRI
Based on predefined MRI settings, imaging can produce multiple sequences where voxel
intensities have different biological meanings for each sequence. One of the habitat revealing
approaches that take advantage of this property, in the case when two or more sequences
are available, is a division of each sequence into two groups based on intensity value: ”High
(H)” and ”Low (L)”. After that, habitats are defined as a partition of voxels into sets based
on intensity groups across all sequences. For example, if two sequences are provided, T1 and
T2 , then four habitats can be detected with four voxel intensity groups: HT 1 -HT 2 , HT 1 -LT 2 ,
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LT 1 -HT 2 , and LT 1 -LT 2 . This method was shown to be predictive for glioblastoma patient
survival time [73–77].
Detailed information about the performance reported in the work referred in this section
papers is provided in Appendix Table D.1.

2.4.2 Dynamic Contrast Enhanced MRI
Compared to multiparametric MRI, where different settings are used to produce a set of
sequences, Dynamic Contrast Enhanced MRI produces multiple sequences using one predefined setting. DCE-MRI represents the reaction of tissue to injected contrast across time.
Commonly, there are four key time points where imaging takes place. A baseline sequence
represents tissue before contrast injection. The washin sequence represents tissue with maximum absorption of injected contrast. The washout sequence represents tissue after the
contrast replacement process starts. Finally, the reperfusion sequence represents tissue with
a minimal concentration of contrast. Thus, DCE-MRI sequences acquired at different time
points can be used in a similar manner to mpMRI sequences.
Golden et al. [78] designed a kinetic matrix. Rows and columns of the matrix correspond
to washin and washout sequence intensities, respectively. Cells of the matrix contained a
numeric value associated with a habitat. A Kinetic (habitat) map is designed as a comparison
of washin and washout intensities using the kinetic matrix for each voxel within a VOI. The
kinetic map was used for analysis. The authors showed that the approach can predict patient
therapeutic response in triple-negative breast cancer.
Similar, to approaches applied for mpMRI, sequences from DCE-MRI can be divided
into high/low-intensity groups. Combinations of intensity groups across sequences define
habitats. Chaudhury et al. [79] using washin and washout sequences showed that the habitats
can be used for estrogen receptor status definition.
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A disadvantage of habitat detection methods by the division of a sequence into high/lowintensity groups is exponential growth of the number of habitats produced with an increasing
number of sequences. Wu et al. [80] described each voxel within a VOI with a feature
vector, where a feature value is an intensity value in a corresponding DCE-MRI sequence.
Clustering was performed to find habitats. First, for each patient, four clusters were defined
independently (patient habitats). Second, cluster centroids from each patient were collected
and clustered for defining three habitats (cohort habitats). Using a coocurrence matrix of
habitats, the authors showed that the approach can be used for breast cancer patient survival
time prediction.
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table D.2.

2.4.3 Texture Metrics
In the case where only one modality and one image sequence is available the methods
described above cannot be applied. The intensities of CT images are correlated with tissue
density. Thus, there is a possibility to design habitat revealing methods based on tissue
structure (texture).
Farhidzadeh [81] divided VOI into small patches and for each patch computed texture
values using the outputs of ImageNet trained [82] convolution layers. For habitat detection,
the author used the result of clustering texture values across patients. The resultant habitats were shown to be predictive in T1 pre/post-contrast and T2 MRI soft tissue sarcoma
metastasis presence classification.
Detailed information about the performance reported in the work referred to this section
papers are described in Appendix Table D.3.
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Chapter 3: Datasets and Tools

3.1

Datasets

3.1.1 The National Lung Screening Trial Dataset
Deidentified data and LDCT images were obtained through the National Cancer Institute
(NCI) Cancer Data Access System (CDAS) [9]. The NLST study design and main findings
have been described previously [7, 8]. Briefly, the NLST was a randomized multicenter trial
comparing screening with LDCT to CXR in high-risk individuals. Eligibility criteria included
current or former smokers aged 55-74 years with a minimum of 30 pack-years smoking history;
former smokers had to have quit within the past 15 years.
The NLST protocol defined a positive screening result as one or more noncalcified nodules
or masses measuring ≥4 mm in axial diameter or, less commonly, other abnormalities such
as adenopathy or pleural effusion [7, 8]. Positive screens were defined in the setting of
abnormalities on baseline screens or abnormalities on follow-up screens that were new, stable,
or that evolved with the latter demonstrating an increase in nodule size, consistency, or other
characteristic potentially related to lung cancer. Participants with positive screening results
received follow-up recommendations; trial-wide guidelines for the management of positive
screens were developed, but were not mandated by protocol.
Negative screens were defined as CT scans with no abnormalities, minor abnormalities
not suspicious for lung cancer, or significant abnormalities not suspicious for lung cancer. In
this analysis, participants who had a negative screening result were not include.
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Figure 3.1: Schematic representations of the NLST patient selection criteria.

Based on the schema originally described in Schabath et al [83], the screen-detected
incident lung cancers and nodule-positive controls are depicted in Figure 3.1.
We identified 196 screen-detected incident lung cancers who had a baseline-positive screen
(T0) that was not diagnosed as lung cancer and then were diagnosed at either the first (T1, N
= 104) or second follow-up (T2, N = 92). Using a 2:1 to nested case-control study design, 392
LDCT screening participants were identified who had three consecutive positive screens (T0
to T2) that were not diagnosed as lung cancer. These NLST participants were designated as
nodule-positive controls in the current analysis. The nodule positive controls were frequency
matched to the lung cancer cases’ age at enrollment (±5 years), sex, race/ethnicity, and
smoking status. This study design minimizes the influence of confounders between the
cases and the controls. As such, radiomic image features that differentiate cases and nodulepositive controls are not likely be attributed to external risk factors. Based on the availability
of complete LDCTs and inability to verify the nodule/abnormality, the 192 lung cancer cases
were reduced to 170. Likewise, the original set of 392 nodule-positive controls was reduced
to 328. Table 3.1 shows demographic details of the selected patients. The lung cases in
cohort 1 were diagnosed at T1 and the lung cancer cases in cohort 2 were diagnosed at T2.
All of the nodule-positive controls had a positive scan from T0 to T2 and never developed
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lung cancer through T7 based on the available NLST data. Cohort 1 was used as a training
set and Cohort 2 as a test set.
The identification of target lung nodules has been previously described [84]. Briefly,
two radiologists reviewed all LDCT images at both the lung window setting (width, 1500
HU; level, -600 HU) and the mediastinal window setting (width, 350 HU; level, 40 HU).
The identification of cancerous nodules among the screen-detected incident lung cancers was
based on data provided by the NLST (ie, locationand size).
Windowing, also known as grey-level mapping, contrast stretching, histogram modification or contrast enhancement is the process in which the CT image greyscale component of
an image is manipulated via the CT numbers; doing this will change the appearance of the
picture to highlight particular structures. The brightness of the image is adjusted via the
window level. The contrast is adjusted via the window width.
The window width (WW) as the name suggests is the measure of the range of CT numbers
that an image contains. A wider window width (2000 HU), therefore, will display a wider
range of CT numbers. Consequently, the transition of dark to light structures will occur
over a larger transition area to that of a narrow window width (<1000 HU).
The window level (WL), often also referred to as window center, is the midpoint of the
range of the CT numbers displayed. When the window level is decreased the CT image will
be brighter and vice versa.
As nodule location was not always available, the senior radiologist [84] identified the
nodules and manually mapped each nodule from T0 to T1. The locations of all nodules in
this analysis are publicly available in the TCIA database (www.cancerimagingarchive.net).
For NLST participants with multiple lung nodules, the largest nodule at baseline (T0) and
subsequent follow-up nodule were used for radiomic feature extraction.
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Table 3.1: Demographic details in NLST cohorts. This table is adapted from Hawkins et
al. [84]
Characteristic
Age, mean ± SD, y
Sex, n (%)
Male
Female
Race, n (%)
White
Black, Asian, other
Ethnicity, n (%)
Hispanic or Latino
Neither Hispanic nor Latino and unknown
Smoking, n (%)
Current
Former
Pack-years smoked, mean ± SD
Current smokers
Former smokers
Self-reported history of COPD, n (%)
Yes
No
FH of lung cancer, n (%)
Yes
No
Stage, n (%)
I
II
III
IV
Carcinoid, unknown
Histologic subtype, n (%)
Adenocarcinoma
Squamous cell carcinoma
Other, NOS, unknown

Lung Cancer
Cases
(n = 170)
63.7 ± 5.11

Nodule-Positive
Controls
(n = 328)
63.5 ± 5.1

p-Value

94 (55.3)
76 (44.7)

192 (58.5)
136 (41.5)

0.28

161 (94.7)
9 (5.3)

315 (96.0)
13 (4.0)

0.49

0 (0.0)
170 (100.0)

2 (0.6)
326 (99.4)

0.55

89 (53.4)
81 (46.6)

175 (53.4)
153 (46.6)

0.85

63.2 (25.8)
64.5 (27.6)

62.0 (21.3)
63.7 (26.8)

0.69
0.83

13 (7.6)
157 (92.4)

19 (5.8)
309 (94.2)

0.44

41 (24.1)
129 (75.9)

56 (17.1)
272 (82.9)

0.07

117 (68.8)
12 (7.1)
21 (12.3)
18 (10.6)
2 (1.2)

—
—
—
—
—

108 (63.5)
38 (22.4)
24 (14.1)

—
—
—

0.66

20

Because algorithms that used the NLST dataset had different requirements for patient
data additional filtering was applied. The resulting number of patients and the filtering
process are described in details at corresponding chapters.

3.1.2 Adenocarcinoma Dataset
At the H. Lee Moffitt Cancer Center & Research Institute, 40 patients diagnosed with
adenocarcinoma tumor(s) in their lungs were divided into two cohorts. For each patient,
contrast enhanced CT was obtained before treatment. There were 20 patients who survived
from 103 to 498 days. Mean survival time was 288 days. These patients were labeled shortterm survivors. There were 20 patients who survived from 1351 to 2163 days with mean
survival time of 1569 days. These patients were labeled long-term survivors and the groups
are representative of the extreme phenotypes. Table 3.2 shows demographic information
about the patients in detail.

3.2

Tools

3.2.1 CT Segmentation and Feature Extraction
A single click segmentation ensemble and subsequent feature extraction were performed
using Definiens software (Definiens, Inc, AG Cambridge, MA, USA). There were 219 features (denoted as Definiens features) extracted to quantify size, shape, location, and texture
information of the pulmonary nodules [4]. The complete list of features used in our analyses
has been previously described [85].
The set of features was reduced to the most consistent (stable) features based on our
previous test/retest analyses. Stable feature sets were defined using two imaging datasets
independently: the RIDER dataset and Cohort 1 from the NLST dataset. The resulting
features were respectively denoted as RIDER stable features and C1 stable features. For
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Table 3.2: Demographic details in the Adenocarcinoma dataset.
Characteristic
Age, mean ± SD, y
Sex, n (%)
Male
Female
Race, n (%)
White
Black, Asian, other
Ethnicity, n (%)
Hispanic or Latino
Neither Hispanic nor Latino and unknown
Tobacco Use, n (%)
Moderate (1-2 PPD)
Light (¡1 PPD)
HIST
None
Cigatettes Nos
Stage, n (%)
I
II
III
IV
Carcinoid, unknown
Histologic subtype, n (%)
Adenocarcinoma
Squamous cell carcinoma
Other, NOS, unknown

Short Survival
Class
(n =20)
69 ± 8.07

Long Survival
Class
(n = 20)
64.45 ± 9.75

p-Value

12 (60)
8 (40)

7 (35)
13 (64)

0.2049

20 (100)
0 (0)

20 (100)
0 (0)

1

1 (5)
19 (95)

0 (0)
20 (100)

1

4 (20)
0 (0)
12 (60)
0 (0)
4 (20)

4 (20)
1 (5)
12 (60)
3 (15)
0 (0)

4 (20)
5 (25)
10 (50)
1 (5)
0 (0)

10 (50)
5 (25)
3 (15)
2 (10)
0 (0)

20 (100)
0 (0)
0 (0)

20 (100)
0 (0)
0 (0)

0.1161

0.0735
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RIDER stable features, two LDCT screenings were performed in a 15-minute interval. For
the C1 stable features using the NLST subjects, T0 and T1 features were utilized as the
test/retest set.
For each Definiens feature, the concordance correlation coefficient [86] was computed
and the dynamic range obtained. Features which had values for both parameters greater
than 0.95 were selected as C1 stable. The stable features were used for experiments on the
Adenocarcinoma dataset.
C1 stable features and RIDER stable features were used in experiments with Adenocarcinoma dataset because follow-up results were unknown for the dataset.
Delta radiomic features were computed for the NLST dataset. Given N time-point imaging, for the dataset patients had up to three screens. Radiomic features were computed for
Tk and Tk+1 imaging time-points. Delta features were defined as the difference of Tk+1 and
Tk features. Potentially, delta features represent changes in nodules after an approximately
one-year interval.

3.2.2 Feature Selection
Even though a test/retest filter was used for initial feature selection, the most predictive
features were used for data classification model design. For that purpose, feature selectors
ReliefF [87–89] (RfF), Correlation-based Feature Selector [90] (CFS), and Minimum Redundancy Maximum relevance [91] (mRMR) Feature Selector were used. Top 5 and top 10
ranked features were used.
There are two main reasons why feature selection was performed. First, it removes
features that are noisy and/or irrelevant for model training. Second, the reduction of a
feature set prevents model overfitting.
There is no formula that gives the optimal number of feature for a given dataset and
a feature set. Nevertheless, Gillies [4] suggested that for each feature used in a model at
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least 10 patients should be presented in a dataset. Having approximately 200 patients in
Cohort 1, that was used as a training cohort, from the NLST dataset the optimal number
of features can be estimated as 20. Because in our feature set the majority of features are
texture characteristics and that these features usually highly correlated among themselves,
we halved this number to 10 features. Also, to check the performance of a model with an
even smaller number of features we halved the estimated optimal number of features. As a
result, we build our models with the top 5 and top 10 ranked features.

3.2.3 Classification
For each training dataset a feature selector was applied in order to simplify the resulting model and remove noisy features. Selected features were used to train a classifier and
after training were used for testing. From multiple possible models, the one that was selected produced the highest AUROC. For each training dataset, the following classifiers were
applied:
• Decision tree-J48 [92];
• Rule-based Classifier-JRIP [93];
• Naive Bayes (NB) [94];
• Support Vector Machine (SVM) [94];
• Random Forests (RFs) [95].
A radial basis function kernel and also a linear kernel were utilized for the SVM classifier.

3.2.4 Synthetic Minority Oversampling Technique
The Synthetic Minority Oversampling Technique (SMOTE) [96] was used because of the
imbalance of case and controls across the various size classes. SMOTE is an oversampling
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approach in which the minority class is over-sampled by creating “synthetic” examples rather
than by oversampling with replacement. To create a synthetic instance, one example (nodule feature vector) is randomly picked from minority class. For that example, five nearest
neighbors in the same class are chosen. Then, one of these neighbors is randomly chosen. For
each numeric feature, the example and its chosen neighbor produce a line segment between
the two features. A new synthetic instance represents a randomly chosen point on the line
segment for each feature. The process repeats with a new example randomly chosen until
the desired number of instances is produced.
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Chapter 4: Nodule Size-Guided Lung Cancer Diagnostic Models and Delta
Radiomics

4.1

Nodule Size-Guided Lung Cancer Prediction
Current guideline algorithms for managing LDCT-detected solid and subsolid nodules are

largely based on size, specifically longest diameter. As recommended by the National Comprehensive Cancer Network (NCCN) [5] and the American College of Radiology (ACR) [4,6],
the current cutoff size for assessing lung nodules increased to 6 mm rather than the 4 mm
originally used in the NLST [7, 8]. Although this increase in threshold positivity has been
reported to decrease false-positive results [3,6,9], decision support tools and lung cancer risk
prediction are still lacking for IPNs ≥6 mm. This section shows that size-specific models
outperform diagnostic models that use entire dataset1 .

4.1.1 Dataset
Experiments for size-guided lung cancer prediction used the NLST dataset that is described in Chapter 3. No additional filtering was used. Each patient was described with
219 Definiens features. Cohort 1 T0 features were used as a training set and Cohort 2 T0
features were used as a test set. Figure 4.1 present longest diameter histograms in the both
cohorts. By substituting values from Cohort 1 longest diameter histogram to Formula 4.1
and Formula 4.2 two threshold values were computed: 8 and 16 mm.
1

This chapter was published in Cherezov, D., Hawkins, S., Goldgof, D., Hall, L., Balagurunathan, Y.,
Gillies, R.J. and Schabath, M.B., 2016, October. Improving malignancy prediction through feature selection
informed by nodule size ranges in NLST. In 2016 IEEE International Conference on Systems, Man, and
Cybernetics (SMC) (pp. 001939-001944). IEEE.. Permission is included in Appendix A.
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t1 =

µc + µnc
−1
2

(4.1)

t2 = t1 · 2

(4.2)

Figure 4.1: Histogram of longest diameter for the lung cancer cases and nodule-positive
controls (A) for the training set (B) and test set.

Resulting thresholds were used to divide the training and the testing datasets into sizegroups: Small (<8mm), Medium (≥8mm and <16mm), and Large (≥16mm). Number of
patients within each cohort and size-group is shown in Table 4.1.
Table 4.1: Number of cases in size-categories.
Cohort
Cohort 1

Cohort 2

subset

Cancer

Non-cancer

total

small

21

112

133

medium

47

57

104

large

17

7

24

small

42

85

127

medium

24

59

83

large

19

8
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4.1.2 Results
4.1.2.1

Impact of Splitting on Accuracy

Splitting datasets leads to a change in workflow. Previously, we used the workflow shown
in Figure 4.2 [97] where all available training data was used to select representative features
and later to train a classifier. During testing, we use all data to evaluate performance. In the
new model, Figure 4.3, after extracting features we add one more step. We check the longest
diameter and define to which subgroup the nodule belongs. Then we do feature selection
and training independently for each group.
We have predictions for three groups. We used results which were obtained from training
on all 261 cases and testing on all 237 cases.
For training, we used the settings shown in Table 4.2 and all the data from Cohort 1.
For testing, we used one (size based) subset of Cohort 2, at a time. Thus, we obtained
the performance for each subset individually. The first row shows results when an SVM
with radial basis kernel function was trained on all cases of Cohort 1 and tested on nodules
from Cohort 2 with LD less than 8 millimeters (a subset of “small” nodules). Similarly,
the second and the third rows show results when the classifier was tested on “medium” and
“large” subsets of Cohort 2 respectively. Finally, the last row shows the result of testing on
Cohort 2 without splitting subsets.
Table 4.3 shows confusion matrices for both cases: when we used all 261 cases of Cohort
1 for training and when we used subsets of Cohort 1 for training.
After dividing Cohort 1 into subsets for training, we tested the corresponding subset from
Cohort 2. Results are shown in Table 4.4. The first three rows show results for testing when
classifiers were trained on a particular subset of Cohort 1 and tested on a corresponding
subset of Cohort 2. The last row shows overall accuracy computed from the summation
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DICOM

segmentation

feature
extraction

predictive
model

prediction

Figure 4.2: Common workflow representation.

Figure 4.3: Common workflow representation.
of confusion matrices for each subset and overall AUROC, which were computed from the
merged probabilities over all three subsets.
Table 4.2: Cancer prediction results without splitting. Cohort 1 was used as a training set
and Cohort 2 was used as a test set.
Feature

Feature

subset

selector

C2 small

Rider stable

C2 medium
C2 large

Test set

C2
w/o splitting

Classifier

Accuracy(%)

AUROC

RfF 10

SVM-rbf

73.22

0.61

Rider stable

RfF 10

SVM-rbf

74.69

0.69

Rider stable

RfF 10

SVM-rbf

81.48

0.69

Rider stable

RfF 10

SVM-rbf

74.68

0.69

When splitting the training dataset, we get results in each subset individually. Overall
accuracy was computed from the summation of confusion matrices for all three subsets and
overall AUROC is the average across the three subsets.
As we can see from Table 4.4 overall accuracy is increased from 74.68% to 81.01%. Also,
we can see the “small” subset benefits the most from splitting datasets. Even though the
“small” subset is the one which is the most imbalanced (21 cases versus 112 cases) and
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Table 4.3: Confusion matrices for cancer prediction with and without splitting.

Small
Medium
Large
Overall

Training

Training

on all

on

261 cases

subsets

CC

NC

CC

NC

CC

11

31

21

21

NC

3

82

3

82

CC

13

11

14

10

NC

10

49

6

53

CC

19

0

19

0

NC

5

3

5

3

CC

43

42

54

31

NC

18

134

14

138

Table 4.4: Results of training on Cohort 1 and testing on Cohort 2 after splitting.
Feature

Feature

subset

selector

C2 small

Rider stable

RfF 5

C2 medium

Rider stable

RfF 10

C2 large

C1 stable

RfF 5

Overall

–

–

Test set

Classifier
Naive
Bayes
SVM-rbf
Random
forests
–

Accuracy(%)

AUROC

81.1

0.78

79.52

0.75

81.48

0.67

81.01

0.79
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SMOTE methods was not used during training, splitting mostly improves accuracy for the
minority class. For the “small” and “medium” subsets we can also see improvements in
AUROC.

4.1.2.2

Impact of Splitting on AUROC

In the previous section, the main goal of training and testing was to evaluate accuracy. If
AUROC is the main factor in choosing parameters then we obtain different feature selectors
and classifiers.
The best AUROC and model settings for the case when we use all the data from Cohort
1 in training are shown in Table 4.5. In the case of splitting Cohort 1 into subsets based on
the LD parameter of a nodule AUROC results are in Table 4.6.
Table 4.5: Best AUROC for training on Cohort 1 without splitting. C2 refers to the
Cohort 2.
Feature

Feature

subset

selector

C2 small

Rider stable

RfF 10

C2 medium

Rider stable

RfF 10

C2 large

Rider stable

RfF 10

Rider stable

RfF 10

Test set

Overall C2
w/o splitting

4.1.2.3

Classifier
Random
forests
Random
forests
Random
forests
Random
forests

Accuracy(%)

AUROC

70.07

0.77

75.9

0.81

74.07

0.74

72.57

0.78

Improving AUROC with Over-sampling

As we can see from the results, splitting Cohort 1 improves overall accuracy. Nevertheless,
one of the disadvantages of splitting is that subsets became imbalanced, except for the
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Table 4.6: Best AUROC for training on Cohort 1 after splitting.
Feature

Feature

subset

selector

C2 small

C1 stable

RfF 10

C2 medium

Rider stable

CFS 5

C2 large

C1 stable

CFS 10

Overall

–

–

Test set

Classifier
Naive
Bayes
Naive
Bayes
Naive
Bayes
–

Accuracy(%)

AUROC

80.31

0.8

75.9

0.81

77.77

0.85

77.5

0.81

“medium” subset. In the “large” subset the minority class is 29.16% of cases. In ‘small‘
subset the minority class is 15.79% of the subset.
Due to the significant difference in the number of cases between minority and majority
classes we applied the SMOTE technique [98] to generate artificial instances for the minority
class and thus balance subsets. For each subset, the number of cases generated by SMOTE
was equal to the difference between the cardinality of the majority and minority classes.
Thus, we balanced subsets and then repeated testing.
Table 4.7 shows the results of testing after applying SMOTE. As we can see, for the
“medium” subset AUROC is improved slightly due to the small number of generated instances. The “large” subset is the one which benefits the most.
For the “small” subset, SMOTE slightly decreased AUROC. The reason is likely the
number of generated instances – 91 artificial. Also, for the “large” subset we used only 3
neighbors for generating a new instance due to the small number of cases in the minority
class (by default the number of neighbors is equal to 5, but there were 7 cases).
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Table 4.7: Results of training on Cohort 1 and testing on Cohort 2 with SMOTE.
Test set
C2 small
C2 medium

4.2

Feature

Feature

subset

selector

C1 stable

CFS 10

219
features

CFS 10

C2 large

C1 stable

CFS 5

Overall

–

–

Classifier
Naive
Bayes
Naive
Bayes
Naive
Bayes
–

Accuracy(%)

AUROC

74.02

0.78

80.72

0.83

81.48

0.87

77.21

0.82

Delta Radiomics Utilization in Lung Cancer Prediction
For all available cases and controls in the NLST dataset, we extracted radiomic features

from the T0 baseline screen and the T1 follow-up screen. To assess changes in nodules after
an approximately one-year interval, we subtracted the T0 and T1 features to generate delta
features. For all patients in our analysis, the median time from randomization to the T1
screen was 375 days (interquartile range = 360-400 days). As such, the time interval to
the T1 screen is relatively consistent for all subjects and eliminates the need to normalize
the delta features with respect to time. This section shows that a combination of baseline
radiomic features with delta features improves IPNs diagnostic accuracy2 .

4.2.1 Dataset
Comparing to experiments in Section 4.1 where features were extracted from a single time
point, delta feature computation required the presence of at least two time-point screens.
Thus, patients who missed the follow-up screening or whose quality of the resulting images
2

This chapter was published in Cherezov, D., Hawkins, S.H., Goldgof, D.B., Hall, L.O., Liu, Y., Li, Q.,
Balagurunathan, Y., Gillies, R.J. and Schabath, M.B., 2018. Delta radiomic features improve prediction for
lung cancer incidence: A nested casecontrol analysis of the National Lung Screening Trial. Cancer medicine,
7(12), pp.6340-6356.. Permission is included in Appendix A.
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were unacceptable for feature computation that were removed from the dataset. Table 4.8
shows the number of patients within each cohort after the additional filtering. Patients from
both cohorts were represented with 219 Definiens features extracted from the baseline screen
and 219 Delta features computed from the baseline and the first follow-up screens. The
training and test cohorts were split into size categories. For higher concordance with clinical
guidelines, such as Lung-RADS [3], for differentiation of small nodules, we used a 6 mm
longest diameter threshold. For differentiation of the large nodule category we used a 16
mm threshold as in Section 4.1.
Table 4.8: Number of patients in delta features experiments.
Cohort
Cohort 1
Cohort 2

Benign
172
135

Malignant
83
77

4.2.2 Results
None of the study population characteristics were significantly different between the training cohort and test cohort and, as previously reported (Table 3.1), none of the study population characteristics are significantly different between the lung cancer cases and nodulepositive controls. The final models for the three nodule size classes (Table 4.9) generally
revealed modest improvements in the performance statistics for models with baseline and
delta radiomic features vs. models with only baseline radiomics. The AUROC for small-sized
nodules was 0.83 (95% CI 0.76-0.90) for baseline-only radiomic features and 0.84 (95% CI
0.77-0.90) for baseline and delta features. For intermediate-sized nodules, the AUROC was
0.76 (95% CI 0.71-0.81) for baseline-only radiomic features and 0.84 (95% CI 0.80-0.88) for
baseline and delta features. For large-sized nodules, the AUROC was higher for baselineonly radiomic features (AUROC = 0.86; 95% CI 0.75-0.91) compared with baseline and delta
features (AUROC = 0.83; 95% CI 0.75-0.91).
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We also computed the overall AUROC (Table 4.9), which included all nodule sizes, for
baseline-only features (AUROC = 0.83; 95% CI 0.82-0.86) and baseline and delta features
(AUROC = 0.86; 95% CI 0.83-0.89). As such, we had a higher AUROC and accuracy for the
large-sized nodule model (0.86) compared with the overall model (0.83). When comparing the
overall model to the intermediatesized nodule model, the overall model had higher AUROC,
but the intermediate-sized model had higher accuracy (0.76 vs 0.74) and specificity (0.92 vs
0.90). When comparing the overall model to the small-sized nodule model, the AUROCs and
specificities were identical for small-sized nodules. The overall AUROC for three size classes
for baseline and delta features was 0.86 (0.83-0.89), which was higher than the AUROCs for
the three size-specific models.
However, the large-sized nodule model had a higher accuracy than the overall model
(0.88 vs 0.78). Likewise, the intermediate-sized nodule model had a higher accuracy than
the overall model (0.80 vs. 0.78).
We also found when we applied the SMOTE method, which over-samples the minority
class creating synthetic minority class examples, some of the performance statistics improved
(Table 4.9).
Because there were only 16 lung cancer cases and 7 nodule-positive controls with large
nodules (≥16 mm), we combined the intermediate- and large groups and repeated the analyses (Table 4.10). As such, when the intermediate-sized nodules and large nodules were
combined into a single group (≥6 mm), the AUROC for baseline only features was 0.80
(95% CI 0.76-0.84) compared with an AUROC of 0.86 (95% CI 0.83-0.89) for baseline and
delta features. The AUROC for the overall model was identical for the large-sized nodule
model; however, the large-sized nodule model has higher accuracy and specificity. Figure 4.4
presents the AUROC plots for the final models for the small nodules and large nodules with
and without SMOTE.
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Table 4.9: Final models for baseline-only and baseline plus delta features. The models
produced the best AUROC.
Features
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta

Baseline
nodule size
Small
(<6mm)
Small
(<6mm)
Small & SMOTE
(<6mm)
Small & SMOTE
(<6mm)
Medium
(6-16mm)
Medium
(6-16mm)
Medium & SMOTE
(6-16mm)
Medium & SMOTE
(6-16mm)
Large
(≥16mm)
Large
(≥16mm)
Large & SMOTE
(≥16mm)
Large & SMOTE
(≥16mm)
Overall
Overall
Overall
& SMOTE
Overall
& SMOTE

AUROC
(95% CI)
0.83
(0.76-0.90)
0.84
(0.77-0.90)
0.77
(0.69-0.85)
0.86
(0.80-0.92)
0.76
(0.71-0.81)
0.84
(0.80-0.88)
0.77
(0.72-0.82)
0.85
(0.81-0.89)
0.86
(0.75-0.91)
0.83
(0.75-0.91)
0.89
(0.82-0.96)
0.8
(0.71-0.89)
0.83
(0.82-0.86)
0.86
(0.83-0.89)
0.81
(0.78-0.84)
0.87
(0.84-0.9)

Accuracy
(95% CI)
0.59
(0.45-0.72)
0.69
(0.57-0.80)
0.77
(0.65-0.88)
0.72
(0.59-0.84)
0.76
(0.70-0.81)
0.8
(0.74-0.85)
0.82
(0.76-0.87)
0.86
(0.81-0.91)
0.76
(0.77-0.99)
0.88
(0.77-0.99)
0.8
(0.66-0.94)
0.8
(0.66-0.94)
0.74
(0.69-0.79)
0.78
(0.74-0.83)
0.81
(0.76-0.85)
0.83
(0.78-0.87)

Specificity
(95% CI)
0.9
(0.78-1.0)
0.9
(0.78-1)
1
(1-1)
0.95
(0.86-1)
0.92
(0.88-0.97)
0.95
(0.92-0.99)
0.87
(0.82-0.92)
0.97
(0.95-1)
0.62
(0.28-0.97)
0.71
(0.36-1)
0.43
(0.04-0.82)
0.57
(0.18-0.96)
0.9
(0.86-0.95)
0.93
(0.90-0.97)
0.87
(0.82-0.92)
0.95
(0.92-0.98)

Sensitivity
(95% CI)
0.26
(0.08-0.44)
0.47
(0.27-0.68)
0.53
(0.32-0.73)
0.47
(0.27-0.68)
0.3
(0.18-0.42)
0.37
(0.24-0.5)
0.68
(0.55-0.8)
0.55
(0.42-0.68)
1
(1-1)
0.94
(0.85-1)
0.94
(0.85-1)
0.89
(0.76-1)
0.45
(0.36-0.55)
0.53
(0.44-0.63)
0.7
(0.61-0.79)
0.61
(0.52-0.7)
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Figure 4.4: AUROC figures for the final models for small nodules without SMOTE (A),
small nodules with SMOTE (B), large nodules without SMOTE (C), and large nodules
with SMOTE (D).

37

Table 4.10: Final models for large nodules (≥6 mm). The models produced the best
AUROC.
Features
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta
Baseline
only
Baseline
+ Delta

Baseline
nodule size
Large
(>6mm)
Large
(>6mm)
Large & SMOTE
(>6mm)
Large & SMOTE
(>6mm)
Overall
Overall
Overall
& SMOTE
Overall
& SMOTE

AUROC
(95% CI)
0.8
(0.76-0.84)
0.86
(0.83-0.89)
0.79
(0.75-0.83)
0.85
(0.82-0.88)
0.8
(0.76-0.83)
0.86
(0.83-0.89)
0.78
(0.75-0.81)
0.85
(0.82-0.88)

Accuracy
(95% CI)
0.75
(0.7-0.8)
0.82
(0.77-0.87)
0.73
(0.67-0.78)
0.8
(0.75-0.85)
0.72
(0.67-0.77)
0.8
(0.75-0.84)
0.74
(0.69-0.79)
0.78
(0.74-0.83)

Specificity
(95% CI)
0.89
(0.85-0.99)
0.93
(0.89-0.97)
0.83
(0.78-0.89)
0.87
(0.82-0.92)
0.9
(0.85-0.94)
0.92
(0.89-0.96)
0.86
(0.81-0.91)
0.88
(0.84-0.93)

Sensitivity
(95% CI)
0.46
(0.35-0.58)
0.6
(0.49-0.71)
0.52
(0.41-0.63)
0.66
(0.55-0.76)
0.41
(0.32-0.51)
0.57
(0.47-0.67)
0.52
(0.42-0.61)
0.61
(0.52-0.7)
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Chapter 5: Habitat Revealing Algorithm

Features associated with heterogeneity of a nodule have one common characteristic: they
compute texture signatures across the entire nodule (Figure 5.1). Knowing that cancer is
heterogeneous and assuming that CT texture represents tissue types with different histology
subtypes, we can conclude that the computation of texture signatures, in this case, is averaging texture features across nodule regions with possibly different histology. As a result,
the averaged texture features may not represent any individual habitat within a nodule. In
this case, the texture of each nodule is considered a unique pattern, which makes the classification process more complicated [99]. For example, consider the case where there are four
habitats that have unique texture signatures: A, B, C, and D. Each nodule contains two
habitats: AA, AB, AC, etc. If we compute the texture signature of an AB nodule the result
will be different from A and B habitat texture signature individually. This difference is the
result of averaging of the texture signature. Thus, each unique combination of habitats in
our case has a unique texture signature. This is illustrated in Figure 5.2.
In this chapter3 a texture analysis method for habitat detection is presented. The approach is based on a computation of circular harmonic wavelets for small patches within
a nodule, then clustering patches in order to define sub-regions of a nodule with similar
patterns (habitats). This approach was used to classify nodules into benign and malignant.
In addition, we used a dataset with 40 patients diagnosed with adenocarcinoma to evalu3

This chapter was published in Cherezov, D., Goldgof, D., Hall, L., Gillies, R., Schabath, M., Mller, H. and
Depeursinge, A., 2019. Revealing Tumor Habitats from Texture Heterogeneity Analysis for Classification
of Lung Cancer Malignancy and Aggressiveness. Nature. scientific reports, 9(1), p.4500.. Permission is
included in Appendix A.
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{F1 ,F2 ,F3 ,...,Fn }

Figure 5.1: Commonly used feature aggregation.

{F11,F12,F13,...,F1n}
{F21,F22,F23,...,F2n}
{F31,F32,F33,...,F3n}
{F41,F42,F43,...,F4n}
{F51,F52,F53,...,F5n}
Figure 5.2: Suggested feature computation output.

ate how effective the approach is for classification of tumor aggressiveness. In this chapter,
we show that habitat features improve lung cancer diagnostic accuracy and lung cancer
adenocarcinoma aggressiveness estimation.

5.1

Dataset
For experiments in this chapter, features extracted from all available time-points in the

NLST were used. Baseline and the first follow-up scan for the training cohort, called Cohort
1, were used. Baseline and both follow-up scans in the test cohorts, called Cohort 2, were
used. Thus, patients who were missing time-point screens were removed from the dataset
as well as patients whose screens had imaging artifacts. Overall, the number of available
patients is shown in the Table 5.1.
Table 5.1: Number of patients from the NLST used for Habitat revealing. Cohort 1 was
used for training and Cohort 2 was used for testing.
Cohort
Cohort 1
Cohort 2

Benign
170
135

Malignant
83
73

40

The adenocarcinoma dataset was used without any additional filtering.
For both datasets, each patient was described by 219 Definiens features plus heterogeneity
features.

5.2

Texture Analysis

5.2.1 Pre-processing
For both datasets, segmentation of tumors was obtained at the H. Lee Moffitt Cancer Center where a qualified radiologist applied a semi-automated 3D segmentation algorithm [100]
and manually edited the result if needed. When a patient had more than one nodule radiologists defined the primary nodule (for NLST it follows the screening records/guidelines).
2D wavelet features are used in this work. Thus, for each primary nodule from both
datasets, we extract one slice where the segmentation area is the largest. We re-sampled
each selected slice such that XY spacing became equal to 0.5 mm. In the case that the
segmentation area of a nodule is less than the area required for a single patch, the original
slice segmentation is used as a patch.Hence, we considered such a nodule to have only one
habitat. For re-sampling we used the bicubic interpolation algorithm implemented in Matlab
R2016b [101].

5.2.2 Circular Harmonic Wavelet Features
We chose to use Circular Harmonic Wavelets (CHW) to characterize local texture properties of a tumor image f (x, y) [102]. CHWs quantify the amount of local circular frequencies,
similar to local binary patterns (LBP) [103]. An interesting property of CHWs is their ability
to characterize image directions in a rotation-invariant fashion at a very low computational
price [104]. This allows quantification of benign or malignant tissue structures independently
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Order
hV 0
hV 1
hV 2
hV 3
hV 4

Figure 5.3: Set of circular harmonics filters used for texture signature computation (hV –
Harmonic Vectors).

of their local orientations. CHWs of order n are constructed in the Fourier domain as

φ̂(n,s) (ρ, θ) = ĥ(2s ρ) ejnθ ,

(5.1)

where (ρ, θ) denote the polar coordinates in the Fourier domain and ĥ(ρ) is a purely radial
bandpass function controlling the wavelet analysis at scale s. Simoncelli’s isotropic collection
of wavelets was used for ĥ(ρ) [105], which proved to work well for analyzing lung tissue in
CT [13]. At a given position (x0 , y0 ), the representation obtained from the collection of the
complex magnitudes of the scalar products |hf, φ(n,i) i| characterizes the local circular frequencies in f of order n = −N : N at a scale s = 1 : S and is locally rotation invariant [106].
This yields a collection of positive response maps having the same dimension as the domain
of f . Features are obtained by averaging each response map over patches.
We consider five collections of circular harmonics. Figure 5.3 shows their impulse responses. For each frequency in a collection we consider three scales (S = 3).
Fourier transformation of a source image decomposes it into its constituent frequencies.
Multiplication of the frequency matrix and a bandpass filter (Figure 5.3), which has the same
resolution as frequency matrix, followed by the conversion of the result into image space is
equivalent to the convolution operation of a source image and a kernel K. The benefit of
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Table 5.2: Number of texture features extracted from each collection.
Collection Order S
# Features

0
3

1
9

2
15

3
21

4
27

the convolution computation in Fourier space, in comparison to its computation in image
space, is that with low computational cost the directions (angle) at which convolution of a
kernel K produces maximum responses for each voxel can be defined i.e. texture features
are computed in a rotation-invariant way.
At the same time, scale (S) increases the size of bandpass filters (Figure 5.3) which
is equivalent to increasing the size of a kernel K in image space. For details, please see
corresponding papers [102, 104].
For each pixel within the segmentation we get a convolution response. In order to detect
texture patterns, we divide nodules into circular patches with radius = 3mm (6 pixels),
shift = 1.5mm (3 pixels) and we average the absolute values of the wavelet responses within
a patch. The choice of the radius of 3mm is based on Lung-RADS (Reporting and Data
System) categories. The procedure was repeated for each set of harmonic vectors (hV)
individually and as a result we obtained five sets of patches for each nodule, where each
patch has a different number of texture features. Table 5.2 shows the overall number of
texture features extracted from each collection.

5.2.3 Habitat Detection
After computing, a set of wavelet features (for each set of harmonic vectors) within
each patch the k-means++ algorithm [107, 108] was applied to identify regions with similar
textures. The number of texture features for each set is shown in Table 5.2. The number
of clusters was estimated with the gap criterion clustering evaluation method [109]. The
maximum number of possible clusters is limited to 15. We do not take patch location into
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Segmented NLST
CT Screen

Wavelet feature
computation

Selecting largest
area slice

Cluster Wavelet
features

x

x
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y

Figure 5.4: Procedure for habitat detection within a nodule. First, the largest area slice is
selected. We split ROI into patches and texture signatures are computed for each patch.
Finally, after k-means++ clustering, habitats are defined as sets of patches. A habitat’s
texture signature is represented as the centroid of the cluster.

consideration during clustering. Because the k-means algorithm depends on the random
starting seed we used a fixed seed. Thus, increasing reproducibility between experiments.
Figure 5.4 represents the workflow for habitat detection in a nodule, which was described
in this section and Section 5.2.2. As a result of the habitat detection step we obtained five
sets of habitats for each nodule with respect to five sets of harmonic vectors.

5.2.4 Habitat Malignancy Estimation
After habitat detection, each nodule is represented as a set of texture signatures for
habitats (Figure 5.2). As was discussed before, histology, and as a result malignancy, of
habitats within a nodule may vary.
In this work, we assume that a difference in habitat histology can be described with
texture patterns. To estimate the probability that a particular habitat belongs to a given
class (malignancy of habitat in the NLST and aggressiveness of habitat in the adenocarcinoma dataset), we applied a leave-one-out cross-validation (LOOCV) on the adenocarcinoma
dataset and the Cohort 1 from the NLST dataset.
Due to the fact that the ground truth of habitat malignancy does not exist, we decided to
not to perform an exhaustive search for a classifier that produce the most correct LOOCV
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results. Several studies showed that Random Forests outperform other classifiers in Radiomics experiments [110–112]. Thus, we chose random forests as a classification model for
malignancy estimation, where the fraction of decision trees which voted that habitat is malignant/aggressive to the total number of decision trees is recorded. This ratio is considered
a pseudo probability of malignancy/aggressiveness.
LOOCV was performed on a patient level. First, a patient was excluded from a dataset/cohort. Then, all habitat texture signatures from the remaining patients with the corresponding patient labels were used for a model training. After training, the excluded patient’s habitat texture signatures were used for testing. The classifier produced a pseudo probability of
malignancy/aggressiveness for each signature. The procedure was repeated for each patient
in the Cohort 1 from the NLST and the adenocarcinoma dataset. Since we did not know
the ground truth about habitats within a nodule we are unable to measure the correctness
of a classifier. Instead, we collected these pseudo probabilities to describe a nodule and see
if this information can be used for the computation of quantitative features that are useful
for a nodule level classification task.
To evaluate malignancy/aggressiveness of habitats in Cohort 2 from the NLST dataset
we used all signatures from the Cohort 1 for training with the assigned labels of the corresponding patient. As before, we did not evaluate the correctness of the classifier, we use
the probabilities it produces to describe nodules. Random forests were used for classification. After this step, for each habitat, we estimated the probability of it being malignant
or aggressive (Figure 5.5). Figure 5.6 shows the algorithm for the malignancy evaluation
described in this section.

5.3

Nodule Heterogeneity Feature Extraction
The detection of habitats within a nodule provides much information about its hetero-

geneity. Nevertheless, it makes it impossible to compare the texture of each nodule directly

45

P(C1)=0.1
P(C1)=0.3
P(C1)=0.8
P(C1)=0.9
P(C1)=0.4

Figure 5.5: Example of the malignancy/aggressiveness probability assignment for habitats
in a nodule.

Centroid values for
all patients and regions

Computing probability
of malignancy/aggressiveness
x

x

y

1.0

y

0.0

Figure 5.6: Estimating habitat malignancy. In the case of the training cohort, the patient
for which we compute the pseudo probability of the habitat malignancy is removed from
the cohort and the remaining patient habitats are used for training the random forest
classifiers with the corresponding patient labels. Removed habitats are provided as input
to the currently trained classifier and the output pseudo probability is considered as the
habitat malignancy level. The procedure is repeated until the habitats of all patients are
estimated. For estimating the malignancy of habitats in the test cohort all patient habitats
of the training cohort were used to train the random forests.
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because the number of habitats differs and because we do not know the relationship between
the habitat area, the level of malignancy/aggressiveness of a habitat and the malignancy of
the nodule itself.
We produced 15 quantitative radiomics features. These features are statistical information of habitat area, habitat pseudo probability of malignancy/aggressiveness and variety in
habitat texture signatures of the nodule. Table 5.3 shows the names of the features and the
corresponding description.
Heterogeneity features were extracted from all patients and were used for nodule classification. Matlab version R2016b was used for all steps of the heterogeneity feature extraction
mentioned above.

5.4

Results
As a baseline for all experiments, we used the results of the classification with Definiens

features (Chapeter 3). Heterogeneity features are 2D features and only texture information
was used to define them. We combined 2D heterogeneity features and 3D radiomics features
to test if such a fusion improves classification performance on the NLST dataset. For experiments with only the heterogeneity features or their combination with 3D Definiens features,
we tested heterogeneity features computed by each frequency collection individually (Figure
5.3).

5.4.1 Lung Cancer vs. Non-Lung Cancer in NLST
Three experiments were based on the Cohorts filtered out from the NLST dataset (see
Figure 3.1) where Cohort 1 was used a training set and the Cohort 2 was used as a test set.
First, we used patient screening results at the time of diagnosis: Cohort 1 at time 1 and
Cohort 2 at time 2. Second, we used patient CT screening one year ahead of diagnosis to
evaluate the heterogeneity of malignant nodules before they were marked as cancer: Cohort
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Table 5.3: Heterogeneity feature description.
Feature name
min P
max P
mean P
median P
min A ratio
max A ratio
mean A ratio
median A ratio
min disjoint A ratio

max disjoint A ratio

mean disjoint A ratio

median disjoint A ratio
Clusters num
mean centroids dist
dist std centroids

Feature description
Minimum value of the malignancy pseudo probability
of a habitat in a nodule.
Maximum value of the malignancy pseudo probability
of a habitat in a nodule.
Mean value of the malignancy pseudo probability
of a habitat in a nodule.
Median value of the malignancy pseudo probability
of a habitat in a nodule.
Minimum value of a habitat area in a nodule.
Maximum value of a habitat area in a nodule.
Mean value of a habitat area in a nodule.
Median value of a habitat area in a nodule.
Minimum value of a habitat area in a nodule in the
case of disjoint parts of a habitats being considered as
different habitats.
Maximum value of a habitat area in a nodule in the
case of disjoint parts of a habitats being considered as
different habitats.
Mean value of a habitat area in a nodule in the
case of disjoint parts of a habitats being considered as
different habitats.
Median value of a habitat area in a nodule in the
case of disjoint parts of a habitats being considered as
different habitats.
Total number of habitats in a nodule.
Computing mean value of habitat texture signatures
for a nodule – nodule texture signature. The result is
mean Euclidean distance from the nodule texture
signature to its habitats texture signatures.
Standard deviation of habitat texture signatures.
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Table 5.4: The best result of heterogeneity experiment. Heterogeneity, Definiens and
combined features of the NLST dataset were used at different screening time points.
Feature
type
Heterogeneity
Definiens
Combined

Diagnosis
AUROC Acc (%)
0.77
72.95
0.83
78.77
0.85
81.64

One year ahead
AUROC Acc (%)
0.69
74.88
0.79
75
0.79
79.4

Two years ahead
AUROC Acc (%)
0.67
65.7
0.78
74.06
0.78
70.53

1 at time and Cohort 2 at time 1. Finally, we use Cohort at time 0 for training and tested
models on Cohort 2 at time 0, which means that for training we use CT screenings of nodules
a year ahead of diagnosis and for testing, we use CT screenings of nodules two years ahead
of diagnosis. The AUROC of classifiers was considered as the primary performance measure.
Table 5.4 shows the results. Heterogeneity helped when combined with 3-D features in all
cases except predicting two years in advance. Table 5.5 shows feature sets, feature selectors
and classifiers producing the best AUROCs. The combined model AUROC was compared to
the Definiens model performance in R by using the pROC library [113] and the comparison
algorithm of DeLong et al. [114]. The P-value of AUROC differences is 0.2215.

5.4.2 Survival Time Prediction in the Adenocarcinoma Dataset
Due to the small number of patients in the adenocarcinoma dataset, we applied crossvalidation for the performance evaluation. Because habitat aggressiveness estimation was
performed with leave-one-patient-out, the same concept was applied when testing nodules.
Cross-validation for this dataset with the Definiens features gave an AUROC = 0.71 and
an accuracy = 77.5% [115]. Using heterogeneity features alone provides the best AUROC of
0.80 and corresponding accuracy of 85%. The enhanced contrast likely enabled better habitat
definition. Again, the combination of features provided the very best results. Table 5.6 shows
the classification models that perform best for particular feature sets with the corresponding
AUROC and accuracy. The combined model AUROC was compared to the Definiens model
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Table 5.5: Overview of classification models that produce the best AUROC. The first
column defines the time point of the CT screening that was used in the training and the
test cohorts. The second column defines which feature set was extracted for a given CT
screening. Heterogeneity refers to only 15 texture heterogeneity features, Definiens refers to
219 features extracted in Definiens. Combined refers to the fusion of Definiens and
heterogeneity features. The feature subset column defines the order of the Circular
Harmonic vectors that were used to extract texture features or a subset of the Definiens
features claimed to be stable on the RIDER or training datasets. The feature selector
column defines one of the feature selectors that produces the best performance. There can
be no feature selector, ReliefF (RfF) with top 10 or 5 ranked features or the minimum
redundancy maximum relevance (mRMR) feature selector. The classifier column defines,
which of the tested classifiers performed the best. From the table we can see that most of
the time random forests (RFs) outperformed other classifiers. Finally, the last two columns
refers to AUROC and accuracy of the corresponding model. ∗ Weka v.3.8.1 provides a
mRMR algorithm whose implementation defines the optimal number of features for a
particular dataset in terms of redundancy and relevance. As a result, selected number of
features vary.
Screening
time
Training Set
Diagnosis
Test Set
Diagnosis

Feature
type
Heterogen.

Training set
Diagnosis-1y.
Training set
Diagnosis-1y.
Training set
Diagnosis-1y.
Training set
Diagnosis-2y.

Heterogen.
Definiens

Definiens
Combined

Combined
Heterogen.
Definiens
Combined

Feature
set
hV4
All 219
features
Training st.
+ hV4
hV3
RIDER st.
All 219
+hV2
hV1
RIDER st.
RIDER st.
+hV0

Feature
Selector
RfF 10

Classifier

AUROC

RFs

0.77

Accuracy
(%)
72.95

mRMR 17∗

RFs

0.83

78.77

none

RFs

0.85

81.64

none
RfF 10

SV Mlin
RFs

0.69
0.79

74.88
75

mRMR 25∗

RFs

0.79

74.4

RfF 10
RfF 5

RFs
RFs

0.67
0.78

65.7
74.06

RfF 10

RFs

0.78

70.53
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Table 5.6: Adenocarcinoma aggressiveness estimation results. ∗ Weka v.3.8.1 provides
mRMR algorithm which implementation defines optimal number of features for particular
dataset in terms of redundancy and relevance. As a result, selected number of features vary.
Feature
type
Heterogeneity
Definiens
Combined

Feature
set
hV3
all 219
features
RIDER
+hV3

Feature
selector
mRMR 1∗

Classifier

AUROC

Acc. (%)

J48

0.80

85

RfF 5

J48

0.71

77.5

RfF 5

RFs

0.91

85

performance in R by using the pROC library [113] and the comparison algorithm of DeLong
et al. [114]. The P-value of AUROC differences is 0.04.
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Chapter 6: Delta Habitat Revealing Algorithm

This chapter describes a fusion algorithm that implements the concept of the three approaches reported in the previous chapters. As a basis for a model and experiment designs,
results from Chapter 5 were used. Texture analysis was applied to reveal habitats. Habitat
maps were computed for the baseline and follow-up CT sequences. We quantified habitat
maps within nodules using a co-occurrence matrix and extracted features out of the resulting
matrix and computed delta features. Finally, we used the combination of baseline and delta
features for lung cancer prediction and diagnosis. In order to compare heterogeneity across
nodules that are similar in size, we split both cohorts into three groups.

6.1

Dataset
Similar to the previous experiments designs Cohort 1 and Cohort 2 from the NLST were

used. Cohort 1 was used as a training set and Cohort 2 as a test set.
For experiments, performed in this Chapter, features were extracted from all available
time-points in the NLST. The baseline and the first follow-up for the training cohort. Baseline and both follow-ups in the test cohorts. Thus, patients who were missing time-point
screens were removed from the dataset, as well as patients whose screens had imaging artifacts. The training and the testing cohorts were split into size groups using longest diameter
(LD): Small (< 6 mm), Medium (6-12 mm), Large(≥ 12 mm). Overall, the number of patients is shown in the Table 6.1. Each patient was characterized by 219 Definiens features,
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219 Definiens delta features and 130 features extracted from habitat maps (those features
are described in detail below).
Table 6.1: Number of patients in delta habitats experiments.
Cohort
Training
Total
Testing
Total

6.2

Size group
Small
Medium
Large
–
Small
Medium
Large
–

Benign
40
120
12
172
20
103
11
134

Malignant
14
28
41
83
18
33
25
76

Total
54
148
53
255
38
136
36
210

Habitat Revealing Algorithm in a Single Time Point CT Image
As the basis for the algorithm design, the method described in Chapter 5 was used.

Compared to the original version of the algorithm changes in particular steps were applied.
The primary goal of the changes is to solve the three following problems: I) Selection of
corresponding slices from the baseline and the follow-up screens from the same anatomical
location. The original habitat revealing algorithm computes a habitat map for a single slice.
For the baseline screen, this slice is selected as the largest nodule segmentation area slice.
In the follow-up screen, it is possible that the largest segmentation area slice will have a
different anatomical location comparing to the baseline screen. By defining the slice at the
baseline screen as the largest nodule segmentation area slice the same anatomical location
should be found in the follow-up screen. II) Habitat maps produced for two time-points
should be correlated (aligned) i.e. if at the baseline there are two habitats (A, B) and at the
follow-up, there are three habitats (C, D, E) we need to know that A is equal to C, B is equal
to D, and E is a new habitat. Otherwise, the estimation of changes will be impossible. III)
Heterogeneity features that were used for habitat description in Chapter 5 are statistical.
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As a result, such features may not be robust to represent changes in habitat. New features
need to be computed.

6.3

Habitat Revealing Algorithm in Sequential Time Point CT Images
The proposed algorithm is similar in design to a habitat revealing method that used a

single time point CT slices, but its components were adapted to process two CT sequences,
the initial and the follow-up, of a single patient.

6.3.1 Pre-processing
All the images were rescaled into 0.5 mm spacing for X and Y axes using the bicubic
interpolation algorithm implemented in Matlab R2016b [101].
From the baseline CT sequence, a slice with the largest nodule segmentation area was selected. Registration similarity metrics were used in order to find the corresponding anatomic
location in the follow-up CT sequence. For each slice in the follow-up sequence, that has a
nodule, registration similarity error with the baseline slice was computed by intensity-based
image registration Matlab R2018a function imregister . The slice with the minimum error
was selected. Overall, two slices are selected, the largest nodule segmentation area slice from
the baseline screen and the slice from the follow-up screen that has approximately the same
anatomical location as the baseline slice.
The training and the test cohort were divided into three groups based on the LD feature
value: Small (<6 mm), Medium (≥ 6 mm & <12 mm), Large(≥12 mm). The lower bound
(6 mm) was taken from Lung-RADS [3] as the differentiation of ”Benign Appearance” and
”Probably Benign” groups. The upper bound (12 mm) was computer as double the lower
bound. The number of patients in each cohort is shown in Table 6.1.
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6.3.2 Texture Map Computation
Similar to the original version of the algorithm, Circular Harmonic Wavelets were used
for texture computation. For details, see Section 5.2.2.
Because texture computation involved image transformation to the Fourier domain with
bandpass filtering, the result depended on the original image size. The original spacing
of the initial and follow-up CTs could vary and because of that two slices could have a
different resolution after they were resampled to 0.5 mm spacing. Taking this into account,
we performed CHW computation for slices in a per-patch way. Both slices were divided
into 32x32 voxel patches and then CHW texture features were computed for all voxels in a
patch. It produced a texture map for a patch. After texture maps were computed for all the
patches, texture maps of a slice were produced by a combination texture maps of composing
patches. For each patient, two texture maps are computed, one for each CT slice.

6.3.3 Habitat Detection
After texture images are computed the images were used for producing habitat maps.
The details can be found in Section 5.2.3. There are several changes applied to this part of
the algorithm.
First of all, in the new version of the algorithm, circular patches were extracted from
each voxel i.e. the stride was decreased from 3 pixels to 1 pixel. Second, the clustering
method was changed from K-Means to Fuzzy C-Means (FCM) algorithm. As a result, if the
optimal number of habitats for K-Means was defined by the Gap cluster evaluation criteria
then for FCM the Dunn Index [116] was used as a metric for evaluating an optimal number
of clusters.
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6.3.4 Habitat Dictionary
Habitat revealing algorithms were performed for each patient independently i.e. on a
patient level. It could be a case that two different patients had ”similar” habitats, but we
considered them to be different. For redundancy removal, we decided to cluster habitats
texture signatures from all patients in the training cohort. The resultant clusters described
habitats on the cohort level. To differentiate them from habitats on a patient-level we called
them a Habitat Dictionary, where a word in a dictionary represented a habitat on the cohort
level.
For the dictionary construction habitats from the training cohort only were used. Similarly to a habitat detection algorithm ( Section 5.2.3) we used the Fuzzy C-Means algorithms
for grouping habitats among patients and the Dunn Index for the choice of an optimal number of clusters with the maximum number of the cluster set to 50.
Dictionary habitat maps were presented as a set of clusters consisting of habitats from
individual patients. As habitat maps on a patient level, for each patient, two dictionary
habitat maps were produced as 2D matrices with the same resolution as a corresponding CT
slice where a cell value was assigned to zero if it referred to a voxel outside of a nodule and
a cell value was assigned to an ID of a word in the dictionary, if it referred the CT voxel was
a part of a nodule. The concept of habitat map construction at a patient level and at the
training cohort level is the same, but the habitats are different because of the difference in
the level of detection.

6.3.5 Malignancy Estimation
Habitat maps represent subregions of a nodule with a similar tissue structure (texture).
It is well known that different populations of cells may have different properties. Because
this method is focused on lung cancer diagnosis, malignancy estimated was performed. Es-
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timation was done for both, habitats extracted from a single nodule (patient level) and for
the habitat dictionary (cohort level).
Malignancy of habitats on a patient level was estimated using the same approach as
described in Section 5.2.4.
Malignancy of habitats on the cohort level (habitat dictionary) for the cohort 1 was
computed as a ratio of cancer patients to the total number of patients in a cluster (word).
For the test cohort, for each patient habitat from the test cohort, we found the closest
word from the dictionary (the minimum Euclidean distance between the habitat and the
word texture signatures) and used the estimated malignancy value of the found word as the
malignancy of the patient habitat.
Overall, as a result of procedures described in Section 6.3, patients from the training
and the test cohort were described with CT slices from two time-points, two habitat maps
computed on a patient-level, and two habitat maps computed on a cohort level. For each
habitat, a pseudo-probability of malignancy was estimated.

6.4

Results
For each CT slice and habitat map, quantitative features were extracted. Delta features

are computed features extracted from the follow-up CT slice or habitat map minus features
extracted from the baseline CT slice or habitat map. The feature set was composed of
the features extracted from the baseline CT slice/habitat map and the delta features. The
produced feature set was used for diagnosis model design.

6.4.1 Quantitative Features
Features that characterized patients can be divided into three groups. First, Definiens
features that were briefly described in the Section 3.2.1. Second, heterogeneity statistical
features described in Table 5.3. Finally, each habitat map (from patient and cohort levels)
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was used for co-occurrence matrix (CM) construction. Usually, a CM is used for texture
analysis in gray-level images where rows and columns represent pixel intensities. In this
paper CM rows and columns represented habitats. Similarly to gray-level images where CM
rows and columns are ordered from low to high intensities, we ordered habitats from low to
high malignancy. The left-most column and the top-most row represented voxels outside of
a nodule. From each CM we extracted 25 features following instructions provided by the
Image Biomarker Standardization Initiative [117] (Habitat co-occurrence features).
For each group of features, delta features were computed as a difference of follow-up and
baseline features. Overall, each patient was characterized by 568 features.

6.4.2 Lung Cancer Classification Model Design
As mentioned in Section 3.1.1, that described the NLST dataset, there are two cohorts.
Patients at Cohort 1 that were diagnosed with cancer had one positive screening at T0,
where nodules were diagnosed as benign, and one follow-up, T1 screen, where nodules were
diagnosed as malignant. Cancer patients from Cohort 2 had T0 and T1 screens where they
were diagnosed as benign and they were diagnosed as malignat at T2.
Thus, two types of experiments were designed: cancer prediction and cancer diagnosis.
For both experiments Cohort 1 T0 and T1 data was used as the training set. For the cancer
prediction experiment Cohort 2 T0 and T1 was using for testing. The goal of this experiment
is to check if habitat features can improve cancer prediction. For the cancer diagnosis
experiment Cohort 2 T1 and T2 where used for testing. The goal of this experiment is to
check if habitat features can improve cancer differentiation. Quantitative features described
in the previous section were extracted for both experiments.
For the described above experiments we used five combinations of quantitative feature
groups to rate and examine their predictive performance. Definiens, Habitat Malignancy,
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Habitat Co-Occurrence feature sets and a combination of Habitat Malignancy with Habitat
Co-Occurrence feature sets were used. Finally, we combined all three groups of feature sets.
For each experiment a classification model was trained using feature selectors and classifiers that were described in Chapter 3. Area Under Receiver Operating Curve (AUROC)
was computed for the test set. A model with the highest AUROC was selected. Resulting
AUROC and its corresponding accuracy for lung cancer prediction and diagnosis are shown
in Table 6.2 and Table 6.3 respectively. Tables 6.4 6.5 describe feature set details used for
training and testing that showed the maximum performance in lung cancer prediction and
diagnosis experiments respectively. Similarly, Table 6.6 and Table 6.7 describe feature selectors and classifiers that were used for model design in lung cancer prediction and diagnosis
experiments respectively.
Table 6.2: AUROC and accuracy (in brackets) of resulting models for lung nodules cancer
prediction in size groups. The training cohort T0 and T1 screens were used for model
design and the test cohort T0 and T1 screens were used for performance evaluation.
Feature set
Habitat Malignancy
Habitat Co-occurrence
Definiens
Habitat Malignancy +
Habitat Co-occurrence
ALL 568 features

Size group
Small
0.79(65.79)
0.83(52.63)
0.88(60.53)

AUROC (Accuracy %)
Medium
Large
0.74(75.74) 0.69(66.67)
0.72(77.21) 0.65(72.22)
0.85(78.68) 0.86(83.33)

Overall
(Accuracy %)
0.78(72.38)
0.79(71.9)
0.85(76.19)

0.8(52.63)

0.75(80.88)

0.67(69.44)

0.67(73.81)

0.86(68.42)

0.82(78.68)

0.88(77.78)

0.81(76.67)
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Table 6.3: AUROC and accuracy (in brackets) of resulting models for lung nodules cancer
prediction in size groups. The training cohort T0 and T1 screens were used for model
design and the test cohort T1 and T2 screens were used for performance evaluation.
Feature set
Habitat Malignancy
Habitat Co-occurrence
Definiens
Habitat Malignancy +
Habitat Co-occurrence
ALL 568 features

Size group AUROC (Accuracy %)
Small
Medium
Large
0.82(52.63)
0.71(75)
0.72(72.22)
0.86(52.63) 0.73(75.74) 0.73(72.22)
0.89(68.42) 0.82(85.29)
0.9(75)

Overall
(Accuracy %)
0.67(70.48)
0.8(70.95)
0.86(80.48)

0.79(52.63)

0.72(75.74)

0.71(72.22)

0.64(70.95)

0.91(63.16)

0.87(84.56)

0.92(72.22)

0.84(78.57)

Table 6.4: Feature set description for texture signature computation and Definiens subsets
in Lung Cancer prediction experiment. Each cell identifies the order of Circular Harmonic
Wavelets in Formula 1 and the Definiens subset of features.
Feature set
Habitat Malignancy
Habitat Co-occurrence
Definiens
Habitat Malignancy +
Habitat Co-occurrence
ALL 568 features

Size group
Small
Medium
Large
2/0/4/4/0/2/-/RIDER -/RIDER -/RIDER
4/-

1/-

0/-

0/RIDER

0/RIDER

4/RIDER

Table 6.5: Feature set description for texture signature computation and Definiens subsets
in Lung Cancer diagnosis experiment. Each cell identifies the order of Circular Harmonic
Wavelets in Formula 1 and the Definiens subset of features.
Feature set
Habitat Malignancy
Habitat Co-occurrence
Definiens
Habitat Malignancy +
Habitat Co-occurrence
ALL 568 features

Size group AUROC (Accuracy %)
Small
Medium
Large
2/4/4/2/0/4/-/RIDER -/RIDER -/RIDER
4/-

4/-

4/-

1/RIDER

3/RIDER

2/RIDER
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Table 6.6: Feature selectors and classifiers produced the maximum AUROC for a given
feature set in Lung Cancer prediction experiment.
Feature
Set
Habitat
Malignancy
Habitat
Co-occurrence
Definiens
Malignancy
& Co-occurance
All
568 features

Small
Feature Classifier
Selector
mRMR10
RFs

Medium
Feature Classifier
Selector
mRMR5 SVMlin

Large
Feature Classifier
Selector
mRMR5
NB

mRMR5

SVMrbf

ReliefF5

SVMlin

ReliefF5

NB

mRMR5
mRMR5

RFs
SVMrbf

None
J48

SVMlin
NB

none
mRMR10

SVMlin
RFs

mRMR5

NB

none

SVMlin

mRMR5

NB

Table 6.7: Feature selectors and classifiers produced the maximum AUROC for a given
feature set in Lung Cancer diagnosis experiment.
Feature
Set
Habitat
Malignancy
Habitat
Co-occurrence
Definiens
Malignancy
& Co-occurance
All
568 features

Small
Feature Classifier
Selector
mRMR10 SVMrbf

Medium
Feature Classifier
Selector
mRMR5
RFs

Large
Feature Classifier
Selector
mRMR5
NB

ReliefF5

SVMrbf

mRMR10

SVMrbf

none

SVMlin

mrMR10
mrMR10

RFs
SVMrbf

none
ReliefF5

RFs
RFs

none
mRMR10

RFs
J48

mrMR10

RFs

ReliefF10

RFs

mRMR10

SVMlin
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Chapter 7: Size Encoding into Texture

In our previous work [18], we presented a CNN model that was trained to predict whether
a benign lung nodule will become a malignant tumor in two years using low dose CT images.
As one of the preprocessing steps, we used a warping technique to resize images to the
CNN’s input resolution. The warping method extracts a patch with a minimum bounding
box, which is enough to include the region of interest (ROI). For a given an ROI, a bounding
box was defined as a rectangle whose width and height were equal to the width and the height
of ROI. The rectangle was located on an image such that it enclosed the ROI. Voxels/pixels
within the rectangle were extracted as a patch. After extraction, the patch is resampled
to the size required for the CNN input. The alternative to warping is cropping. Cropping
extracts an ROI patch with size equal to the CNN input image, thus resampling is not used.
Figure 7.1 shows a visual representation of the warping and cropping methods.
The warping method scales the X, and Y axes of an image using Sx , Sy coefficients
respectively. These scaling coefficients depend on the size of an ROI. We hypothesize4 that
a CNN may learn texture specific modifications associated with resampling and as a result
learn the size of an ROI, i.e. a CNN learns an object’s (nodule’s) size when the warping
method is used. In lung cancer diagnosis, nodule size represented by the ROI is a highly
predictive feature, thus a CNN may learn one of the most predictive diagnostic features.
4

This chapter was published in Cherezov, D., Paul, R., Fetisov, N., Gillies, R.J., Schabath, M.B., Goldgof,
D.B. and Hall, L.O., 2020. Lung Nodule Sizes Are Encoded When Scaling CT Image for CNN’s. Tomography,
6(2), p.209. Permission is included in Appendix A.
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A
Y = 100 pix

X = 100 pix

CNN

Scaling

Y * Sy = 100 pix

X * Sx = 100 pix
X < 100 pix
Y < 100 pix

B

CNN input

CNN input

CNN

Figure 7.1: Patch extraction methods (A) Cropping and (B) Warping. The solid line
represents the region of interest border. The dashed line represents an extracted patch
border. This assumes that CNN input is a 100x100-pixel image. X and Y represent the
corresponding patch’s width and height, respectively.

7.1

Previous Works
In NLST, for our experiments, we chose a CNN architecture and pre-trained model

presented by Paul et al. [18] because the authors used the same dataset for training the
model and showed up-to-date performance. The original model was trained to predict if a
benign nodule will evolve into a malignant tumor in two years. Following our hypothesis,
this trained model could (and did) learn nodule sizes from texture as well as malignancy
characteristics. We studied this question in experiments described below.
The CNN model was a cascade network. There are two branches (”left”/”right”). The
”left” branch consists of a max-pooling layer before merging. The ”right” branch consists of
two convolution layers where each of them were followed by a max-pooling layer. After the
second max-pooling layers the ”right” and the ”left” branches are merged. After merging
there are a convolution and max-pooling layer. Their result represented as a vector (flattened) is used as an input to a single fully connected layer, which is considered an output
layer in the architecture. The CNN model showed 76% accuracy on the NLST dataset. De-
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tailed information about the architecture and performance of the model can be found in the
original paper.
In comparison, Hawkins et al. [84] used 219 Radiomics features (size, location intensity
and texture features) extracted from each patient in NLST cohorts, to build a conventional
radiomics model (Naive Bayesian, Random Forests, SVM classifiers) to predict if an indeterminate nodule will evolve into a malignant tumor in two years. As a baseline result, Hawkins
used the accuracy of the ROI volume feature only. The accuracy of the volume feature was
71.6%. A complete list of experiments and detailed information about results can be found
in the original paper.

7.2

Experiment Design
Design of experiments using the NLST dataset was focused on three questions: 1) Is a

CNN model capable of learning an original nodule’s size after image resampling? 2) Is a
CNN model capable of using encoded size information in its decision-making process? 3)
Does the model from our previous work implicitly use encoded size information?
Because our assumption is not based on lung cancer diagnosis, we relabeled patients.
Labels in this study represent the size of a nodule: small or large. Different categorization
methods can be used for relabeling. To analyze model performance and stability we used five
methods for categorization. Longest diameters for a nodule of 6, 8 and 10 millimeters were
used as a threshold for splits. They were chosen because they are considered representative
milestones in the evolution of a nodule according to Lung-RADS [14].
As shown in Figure 7.1, scaling parameters, Sx and Sy , for patch length and height,
respectively, are independent. The smaller the length/height the larger the corresponding
scaling factor and influence on texture. Thus, for each patch, we selected the smallest of the
two values, length or height. For labeling, as a threshold, we used a median of the smallest
values in the training cohort. Finally, as a threshold value, we used the median value of
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a nodule ROI area in pixels. The numbers of patients within each class for all labeling
approaches are shown in Table 7.1. Cohort 1 T0 was used as a training dataset. Cohort 2
at T0, T1, and T2 were used as an unseen test cohort.
Table 7.1: Number of patients in groups after labeling nodules by size. The number of
patients in Cohort 2 at T0 and T1/T2 vary because some patients were excluded due to
low image quality or patient removal from the trial.
Threshold
LD 6
mm
LD 8
mm
LD 10
mm
Median of
min axe
Median
nodule area
Total

Cohort 1 T0
Small Large

Cohort 2 T0
Small Large

Cohort 2 T1
Small Large

Cohort 2 T2
Small Large
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204

44

193

39

171

44

166

129

132

126

111

106

104

89

121

183

65

172

65

140

70

126

84

122

139

89

148

128

82

124

86

128

133

99

138

123

87

117

93

261

237

210

210

First, (Experiment 1), we trained a CNN model from scratch using Paul’s architecture [18]. All weights are randomly initialized and the model was trained on Cohort 1 to
classify nodules with respect to one of the size labeling methods described above. The goal
of this experiment was to determine how much information about the size of a nodule is
encoded into the texture by resampling and can be extracted by a CNN.
Second, (Experiment 2), we tuned the CNN model created in Experiment 1, which was
originally trained to classify nodule size. The model was tuned (100 epochs with 0.0001
learning rate, 0.1 dropout) to predict if a benign nodule evolves into a malignant nodule
in two years. Learning rates for all convolution layers were set to zero, fixing the features
extracted from the image, and the last fully connected layer was randomly reinitialized. The
goal of this experiment was to determine if when encoded by scaling and decoded by CNN,
size information can be used in decision-making process for Lung Cancer diagnosis.
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Third, (Experiment 3), we tuned Paul’s pre-trained CNN model designed to predict if a
benign nodule will evolve into a malignant tumor in two years. The model was tuned (100
epochs with 0.0001 learning rate, 0.1 dropout) to predict nodule size. A detailed description
of the model can be found in our previous work [18]. Learning rates for all convolution layers,
which would have extracted features from the images, were set to zero and the last layer,
fully connected, was randomly reinitialized. The goal of this experiment is to determine how
much information about nodule size was used by Paul’s CNN [18].
In the experiments 1 and 2 Cohort 1 T0 was used for a training and Cohort 2 T0, T1,
T2 were used for testing. For comparability with our previous results in experiment 3 we
used Cohort 1 T0 for training and Cohort 2 T0 for testing.

7.3

Results
Results of Experiment 1 (Table 7.2) show that a CNN model can distinguish the difference

between small and large nodules with high accuracy. Labeling using 6, 8 and 10 mm of a
nodule’s longest diameter as a threshold showed smaller accuracy values compared to other
labeling methods. Potentially this is caused by the fact that the longest diameter length
does not take into account lengths of nodule projections onto axes, which, as we discussed
above and showed in Figure 7.1, define Sx , Sy scaling factors and as a result, encode size into
image texture.
Hawkins et al. [84] used the accuracy of an ROI volume feature in a baseline performance
model for the prediction that a benign nodule evolves into a malignant tumor in two years.
In that experiment, accuracy was 71.6%. Paul et al. [18] using the same dataset, but a CNN
for a nodule classification improved the accuracy to 76%. These values can be considered
as lower and upper bound values for Experiment 2. In the experiment we tuned a CNN
model, trained to classify the size of an ROI, to classify if a benign nodule will evolve into a
malignant tumor in two years. Following our assumption that if a CNN learns to extract the
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Table 7.2: Accuracy and AUROC (in brackets) of a CNN trained from scratch for
classification a nodule original size group (Experiment 1).
Threshold
LD 6
mm
LD 8
mm
LD 10
mm
Median of
min axis
Median
Nodule area

Cohort 2 T0 (%)
95
(0.97)
89
(0.947)
94.5
(0.9784)
99.0
(0.9998)
94.93
(0.9894)

Cohort 2 T1 (%)
79.52
(0.85)
79
(0.839)
87
(0.867)
92.38
(0.94)
97.14
(0.9978)

Cohort 2 T2 (%)
81.4
(0.85)
76
(0.82)
84
(0.877)
94.28
(0.95)
95.7
(0.9974)

size of ROI then the CNN’s accuracy should not be significantly smaller than the baseline
result provided by Hawkins, though performance using 2D versus 3D features may vary.
Paul’s CNN model was trained from scratch to predict the malignancy of a nodule. Thus,
results of a tuned model in Experiment 2 would not be expected to be higher because most
probably Paul’s CNN model learned to extract additional texture features associated with
cancer compared to a model trained to extract size information.
Results from Experiment 2 (Table 7.3) show that a CNN trained to classify nodule size can
be used for diagnosis. Nevertheless, due to the fact that accuracy values in the experiment
are consistently smaller than the accuracy of the CNN trained for diagnosis, we can surmise
that the model from our previous work [18] learns additional image characteristics.
Table 7.3: Accuracy and AUROC (in brackets) of a CNN trained for nodule original size
classification after tuning for cancer classification (Experiment 2). Accuracy of a CNN
trained from scratch to classify cancer is 76%. Accuracy of cancer classification using a
tumor volume only is 71.6%.
Threshold

LD 6 mm

LD 8 mm

LD 10 mm

Accuracy (%)

72.16
(0.76)

74.26
(0.788)

75.1
(0.8182)

Median of
min axis
74.26
(0.786)

Median
nodule area
74.26
(0.794)
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Results from Experiment 3 (Table 7.4) show that the CNN model trained for nodule
malignancy prediction [18] can be used for nodule size detection and as a result, we assume
that nodule size is a feature of the image that the model learned.
Table 7.4: Accuracy and AUROC (in brackets) of a CNN trained for cancer classification
after tuning to classify a nodules original size group (Experiment 3).
Threshold
LD 6
mm
LD 8
mm
LD 10
mm
Median of
min axis
Median
Nodule area

Cohort 2 T0 (%)
93.67
(0.969)
90.3
(0.923)
93.67
(0.9763)
100
(1)
97.87
(0.989)

Cohort 2 T1 (%)
79.52
(0.82)
81
(0.8438)
87.14
(0.9235)
92.4
(0.937)
98.57
(0.989)

Cohort 2 T2 (%)
81.4
(0.858)
80.5
(0.828)
84.76
(0.907)
94.3
(0.962)
98.09
(0.99)
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Chapter 8: Discussion

Chapters 4 and 6 describe size-guided lung cancer diagnostic models. The primary assumption tested in these chapters is that lung nodules from different size groups have different
biomarkers that are used for nodule differentiation. During the experiments, multiple threshold values were used for splitting the NLST cohorts into size groups. Overall, thresholds of
8 and 16 mm were used for the definition of “small”, “medium”, and “large” groups. Then,
6 and 16 mm were used for size group definition such that “small”, “medium”, and “large”
groups were defined and only of “small” and “large” groups were defined using only a 6 mm
threshold. Finally, 6 and 12 mm were used for splitting the cohorts into size-groups. Despite the fact that different thresholds were used for splitting, size-guided workflow showed
improvement in diagnostic performance. Based on the observed results we can say that the
assumption is correct for the NLST dataset, nevertheless, further research is needed in order
to establish how many size groups should be used and what thresholds should be used for
the splitting.
Another open question related to size-guided diagnosis is performance evaluation. Clinicians commonly making decisions for questions that have a different level of risk for a patient
e.g. assign a follow-up screen in three months or in a year, and assign biopsy for a patient
or not. In the first question if a doctor makes a mistake then in the worst-case scenario
it will postpone the diagnosis of a patient. In comparison, a biopsy is a clinically dangerous procedure and 5% of patients who get a biopsy die. Thus, clinicians prefer to evaluate
classification or prediction models with AUROC. It provides information about potential

69

model performance for a different level of thresholds for decision making (confidence). In
comparison to model accuracy, AUROC computation for multi-modal systems, such as sizeguided diagnosis, is currently not available. Accuracy computation uses a fixed threshold for
labeling an instance based on a classification score (0.5). Thus, if multiple models produce
sets of scores then overall accuracy can be computed by merging these sets into a single one,
applying a threshold (0.5) for labeling and computation of accuracy from a confusion matrix.
AUROC computation gives a numeric value that characterizes how well two distributions
of pseudo-probabilities split: 0.5 if there is a random split and 1 if there is a perfect split.
In contrast to accuracy computation, multi-model systems AUROC cannot be computed by
merging sets of pseudo-probabilities. Such a computation approach leads to the fusion of
the distribution of scores and produces a non-representative result. For example, consider
two models. Model1 produced scores for Class1 0.2, 0.3, and 0.4 as well as scores for Class2
are 0.5, 0.6, and 0.7. Model2 produced scores for Class1 0.55, 0.65, and 0.75 as well as
scores for Class2 are 0.8, 0.9, and 1. For both models, AUROC is equal to 1. When we
merge scores from Model1 and Model2, Class1 scores are 0.2, 0.3, 0.4, 0.55, 0.65, and 0.75.
Similarly, Class2 scores are 0.5, 0.6, 0.7, 0.8, 0.9, and 1. AUROC for the new distributions
is equal to 0.83. As we can see, the resultant score distribution has lower a AUROC value
than distributions from the models independently.
For our research, we computed the overall AUROC by merging pseudo-probabilities, but
considering the example provided above, we can say that performance for size-guided groups
should be evaluated independently.
Chapters 4 and 6 provide details for delta features utilization. Delta features were computed as a difference of features extracted from the follow-up screen and features extracted
from the baseline screen. The presented results show that combination of single time-point
features and delta features improves diagnostic performance. For the experiments we used
the NLST dataset. According to the protocol, a subject got an annual screening. Thus,
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delta features computed in our study measured changes occurring within a nodule within an
approximately one-year period. At the same time, if a patient has a suspicious nodule that
can be characterized as benign, but may evolve into a malignant tumor in a short period
of time, then the follow-up screen may be arranged in three months. Thus, there can be
different biomarkers for the case where a patient get a follow-up in a year and for the case
where a patient got a follow-up in three months.
Similarly, delta features can be used for treatment response prediction where in comparison to a diagnostic screen CT imaging is performed with contrast. Nevertheless, using
pretreatment CT and the follow-up acquired a small term after treatment therapy started
to extract representative biomarkers for treatment result prediction is of unknown efficacy.
Chapters 5 and 6 introduce texture analysis algorithms for revealing habitats within
a nodule. Presented results in the chapters show that the combination of heterogeneity
features improves lung nodule diagnosis without statistical significance and improves tumor
aggressiveness estimation accuracy statistically significantly. Presumably, the difference in
the impact of heterogeneity features on the diagnostic and aggressiveness estimation tasks
can be explained with the difference in abnormal mass sizes in the dataset. The NLST
is a screening dataset and the Longest Diameter (LD) of nodules varies from a couple of
millimeters up to 50 mm. The majority of patients have nodules with LD less than 10 mm.
It makes the habitat revealing algorithm inefficient because it is impossible to split a small
nodule into even smaller habitats. Another potential difference in impact is that screening
used low-dose CT where pretreatment CT has done with contrast that increases descriptive
properties of the resulting image.
CT texture information was used for the local characterization of the tissue structure.
This information was used for splitting the ROI into sub-regions with similar texture (habitats). Heterogeneity features that characterize habitats improved lung adenocarcinoma aggressiveness classification statistically significantly. Nevertheless, texture computation is
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sensitive to size, as we discussed above, and the shape of a nodule. For example, texture
computation on the edge of the nodule will produce a different result in comparison to the
center of the nodule even though biologically tissue on the edge and in the center of the
nodule may belong to the same habitat. Thus, currently, it is hard to say how well texture
signatures differentiate biological habitats.
Size is one of the most important clinical features in cancer diagnosis. As we can see
from Chapters 4 and 6, size-guided analysis improves diagnostic model performance. At the
same time, CNN models use only imaging data. In Chapter 7 we provided experimental
evidence that warping (up-sampling) encodes size information into texture and a CNN is
able to decode this information and use it for decision making. Questions: is it possible to
encode other information?
Radiomics, as a cross-disciplinary field, uses clinical data, imaging data, and machine
learning tools. It was considered that when CNN models are used it will be hard to include
clinical features into a model. Nevertheless, we showed that at least in our previous models
the CNN learned to decode a nodule’s size and used it in its decision-making process. As
a result, this raises a question. Is it possible to encode some other clinical feature (or
features) into medical images such that a CNN model could use it and which will benefit
the performance of the model? As we will note, there are some examples when it occurs.
A model recognized hospitals, departments, and scanners from chest X-Ray images because
this information was related to pneumonia risk score [118]. In our work, the CNN model was
able to learn tumor size because the size is an important feature in Lung Cancer diagnosis
and malignancy prediction. In these examples, clinical information was encoded accidentally
and researchers did not choose what information to encode. Thus, the question is if it is
possible to control that process?

72

Chapter 9: Conclusions

9.1

Summary
Nodule classification Area Under Receiver Operating Curve (AUROC) in the NLST

dataset was improved from 0.69 to 0.79 by developing systems for nodule size-groups independently. The inclusion of delta features enhanced CAD classification AUROC to 0.86
in the NLST. Features that were produced by the habitat revealing algorithm statistically
significantly improved lung cancer patient survival time classification AUROC from 0.71
to 0.91 in the adenocarcinoma patients. Finally, AUROCs of 0.91, 0.87 and 0.92 were
achieved for “small”, “medium” and “large” size-groups in the NLST dataset by combining
delta-habitat and conventional radiomic feature sets. A CNN model trained from scratch
to differentiate ”small”/”large” nodules and a CNN model, that originally was trained to
classify cancer/non-cancer nodules, tuned to classify size categories showed accuracy more
that 80% and AUROC more then 0.80 for a variety ”small”/”large” labeling methods.

9.2

Contributions
In Chapter 4 a size-guided lung cancer diagnostic workflow is presented. In comparison to

the workflow where all the data is used for the training of a model for a nodule classification
the proposed method uses multiple models where each model is trained to classify nodules
from a particular size category. The presented workflow increases performance of nodule
classification using the same number of patients in a training dataset.
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Certain patients got CT screening annually. As an extension of size-guided analysis
(Chapter 4) we showed that size-guided lung cancer diagnostic workflow performance can
be improved by complementing a feature set with delta features. We defined delta features
as the difference of features extracted from a follow-up CT and features extracted from a
baseline CT.
In Chapter 5, a new habitat revealing algorithm is presented. The algorithm uses texture
signatures to characterize tissue structure locally. In comparison to alternative algorithms
where the number of habitats were manually defined, the presented algorithm uses the Gap
clustering indexing metric to estimate “optimal” number of habitats within a given nodule.
In addition, a Random Forests classifier was used for estimation of malignancy/aggressiveness
of a habitat using the training dataset.
In Chapter 6, a fusion approach for lung cancer diagnosis was presented. The approach
uses a size-guided habitat revealing algorithm based on two time-point screen results. The
presented fusion algorithm outperforms individual approaches presented in Chapter 4 and
Chapter 5.
In comparison to chapters discussed above, Chapter 7 is focused on CNN model explainability rather than a classification or prediction model design. Results of experiments shown
in the chapter show that warping (up-sampling) of images encodes object size information
into texture and that a CNN of capable to decoding this information and use it for decision
making.

9.3

Future Directions
The common element among the frameworks described above is a single timepoint image

database. For example, the most frequent experimental design for the treatment response
study involves pretreatment imaging only.
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Figure 9.1: A 38-year-old man with BRAF-mutant melanoma and miliary, subcutaneous
metastatic deposits. Photographs were taken (A) before initiation of PLX4032, (B) after
15 weeks of therapy with PLX4032, and (C) after relapse, after 23 weeks of therapy.
Reprinted with permission. c (2019) American Society of Clinical Oncology. All rights
reserved. Wagle N. et al. Dissecting therapeutic resistance to raf inhibition in melanoma
by tumor genomic profiling. J Clin Oncol, 29(22):3085, 2011.

In contrast, Henning [119] used DWI and T2 MRI sequences in a RIF-1 mouse model to
reveal habitats. The designed method was used for the examination of processes within a
tumor during radiotherapy [120]. Authors showed that habitats vary in radiosensitivity and
as a result, response to the treatment among habitats was significantly different.
After initially ”successful” chemo/radio-therapy (significant decrease in tumor volume),
follow on treatment of a patient has no or low effect due to an increasing number of drugresistant cells in a tumor [121, 122]. Wagle et al. [123] provide an image of a 38-year-old
man with BRAF-mutant melanoma and miliary, subcutaneous metastatic deposits before
the targeted treatment, after 15 and 23 weeks of treatment (Figure 9.1).
Clinical potential of temporal information about a nodule (e.g. changes within a tumor during treatment) has had little study in Radiomics. Several studies where authors
used results from multi-time point imaging were found. Balagurunathan et al. [124] showed
that change in nodule volume between initial screening and the follow up (delta volume)
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can be used as a malignancy biomarker. Similarly, Alahmari et al. [125] and Cherezov et
al. [126] showed that a combination of Radiomics features and delta features (difference
of Radiomics features extracted from initial screening and follow-up) improve lung cancer
diagnosis. Henderson et al. [127] showed that chemotherapy significantly changes the entropy feature between baseline and interim examinations in breast cancer. Xu [128] used a
pre-trained CNN with a recursive layer for treatment response prediction using serial CT
sequences (pre-treatment and three follow-ups).
Heterogeneity is shown to be an important cancer descriptor both for diagnosis and
treatment as well as associated with a wide specter of clinical questions. There are methods
for heterogeneity and habitat evaluation for different types of cancer and modalities. Most
studies, overviewed in this work, target processing images from a single time point. This
approach limits dynamic data about tumor evaluation.
Zhang et al. [129] showed the result of a new treatment strategy simulation. Compared
to a conventional treatment approach where the maximum tolerated dose (MTD) of a drug
is used, the proposed method suggests to reduce a drug dose in order to prevent the death
of all drug-sensitive cells, but enough to stop tumor growth (Figure 9.2). Hypothetically, it
can increase time to progression.
Radiomics may provide non-invasive methods for drug-sensitive and resistant types of
tissue estimation. That information, later, can be used for required drug dose computation
similarly to the above-described treatment strategies. The design of such Radiomics methods
requires analysis of multi-time point image data.
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Figure 9.2: Illustration of the designed evolutionary dynamics in adaptive therapy. The
purple cells are sensitive to the treatment and the green cells are resistant. The graphs
represent the simulated density of each population over time during treatment. The top
row represents standard therapy in which the maximum tolerated dose is given
continuously after initiation. The cells sensitive to treatment are eliminated quickly. This
intensely selects for cells that are resistant to the treatment, in this case T- cells, and
eliminates the competition effects of the T+ population, resulting in competitive release
with rapid treatment failure and tumor progression. The bottom row represents an
evolution-based strategy in which therapy is halted before all of the sensitive cells are
eliminated. In the absence of therapy, the sensitive cells out-compete the resistant cells due
to their fitness advantage. This “steers” the tumor back to the pretreatment stage so that
it remains sensitive to treatment. The resistant cells, or T- population, will increase
slightly with each cycle so that this treatment eventually fails. However, mathematical
models demonstrate control may be durably maintained for up to 20 cycles - significantly
longer than continuous therapy. This figure is adapted from Zhang et al [129].
9.4
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A. Martineau, O. Pradier, R. Hustinx et al., “18f-fdg pet uptake characterization
through texture analysis: investigating the complementary nature of heterogeneity
and functional tumor volume in a multi–cancer site patient cohort,” Journal of nuclear
medicine, vol. 56, no. 1, pp. 38–44, 2015.
[50] S. Ha, S. Park, J.-I. Bang, E.-K. Kim, and H.-Y. Lee, “Metabolic radiomics for pretreatment 18 f-fdg pet/ct to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis,” Scientific
reports, vol. 7, no. 1, p. 1556, 2017.
[51] R.-F. Chang, H.-H. Chen, Y.-C. Chang, C.-S. Huang, J.-H. Chen, and C.-M. Lo,
“Quantification of breast tumor heterogeneity for er status, her2 status, and tn molecular subtype evaluation on dce-mri,” Magnetic resonance imaging, vol. 34, no. 6, pp.
809–819, 2016.
[52] C. Dennie, R. Thornhill, C. A. Souza, C. Odonkor, J. R. Pantarotto, R. MacRae,
and G. Cook, “Quantitative texture analysis on pre-treatment computed tomography
predicts local recurrence in stage i non-small cell lung cancer following stereotactic
radiation therapy,” Quantitative imaging in medicine and surgery, vol. 7, no. 6, p. 614,
2017.
[53] X. Dong, P. Wu, X. Sun, W. Li, H. Wan, J. Yu, and L. Xing, “Intra-tumour 18
f-fdg uptake heterogeneity decreases the reliability on target volume definition with
positron emission tomography/computed tomography imaging,” Journal of medical
imaging and radiation oncology, vol. 59, no. 3, pp. 338–345, 2015.
[54] Y. Liu, S. Liu, F. Qu, Q. Li, R. Cheng, and Z. Ye, “Tumor heterogeneity assessed
by texture analysis on contrast-enhanced ct in lung adenocarcinoma: association with
pathologic grade,” Oncotarget, vol. 8, no. 32, p. 53664, 2017.

84

[55] K. Miwa, M. Inubushi, K. Wagatsuma, M. Nagao, T. Murata, M. Koyama, M. Koizumi,
and M. Sasaki, “Fdg uptake heterogeneity evaluated by fractal analysis improves the
differential diagnosis of pulmonary nodules,” European journal of radiology, vol. 83,
no. 4, pp. 715–719, 2014.
[56] Y. Liu, X. Xu, L. Yin, X. Zhang, L. Li, and H. Lu, “Relationship between glioblastoma
heterogeneity and survival time: An mr imaging texture analysis,” American Journal
of Neuroradiology, vol. 38, no. 9, pp. 1695–1701, 2017.
[57] Y. Liu, X. Zhang, N. Feng, L. Yin, Y. He, X. Xu, and H. Lu, “The effect of glioblastoma
heterogeneity on survival stratification: a multimodal mr imaging texture analysis,”
Acta Radiologica, vol. 59, no. 10, pp. 1239–1246, 2018.
[58] C. Su, J. Jiang, S. Zhang, J. Shi, K. Xu, N. Shen, J. Zhang, L. Li, L. Zhao, J. Zhang
et al., “Radiomics based on multicontrast mri can precisely differentiate among glioma
subtypes and predict tumour-proliferative behaviour,” European radiology, vol. 29,
no. 4, pp. 1986–1996, 2019.
[59] B. Ganeshan, E. Panayiotou, K. Burnand, S. Dizdarevic, and K. Miles, “Tumour heterogeneity in non-small cell lung carcinoma assessed by ct texture analysis: a potential
marker of survival,” European radiology, vol. 22, no. 4, pp. 796–802, 2012.
[60] V. S. Parekh and M. A. Jacobs, “Integrated radiomic framework for breast cancer and
tumor biology using advanced machine learning and multiparametric mri,” NPJ breast
cancer, vol. 3, no. 1, p. 43, 2017.
[61] A. Chaddad, S. Sabri, T. Niazi, and B. Abdulkarim, “Prediction of survival with multiscale radiomic analysis in glioblastoma patients,” Medical & biological engineering &
computing, vol. 56, no. 12, pp. 2287–2300, 2018.
[62] P. Prasanna, P. Tiwari, and A. Madabhushi, “Co-occurrence of local anisotropic gradient orientations (collage): a new radiomics descriptor,” Scientific reports, vol. 6, p.
37241, 2016.
[63] J. J. Van Griethuysen, A. Fedorov, C. Parmar, A. Hosny, N. Aucoin, V. Narayan, R. G.
Beets-Tan, J.-C. Fillion-Robin, S. Pieper, and H. J. Aerts, “Computational radiomics
system to decode the radiographic phenotype,” Cancer research, vol. 77, no. 21, pp.
e104–e107, 2017.
[64] K. Skogen, A. Schulz, E. Helseth, B. Ganeshan, J. B. Dormagen, and A. Server, “Texture analysis on diffusion tensor imaging: discriminating glioblastoma from single brain
metastasis,” Acta Radiologica, vol. 60, no. 3, pp. 356–366, 2019.
[65] J. Wang, F. Kato, N. Oyama-Manabe, R. Li, Y. Cui, K. K. Tha, H. Yamashita,
K. Kudo, and H. Shirato, “Identifying triple-negative breast cancer using background
parenchymal enhancement heterogeneity on dynamic contrast-enhanced mri: a pilot
radiomics study,” PloS one, vol. 10, no. 11, p. e0143308, 2015.

85

[66] S. Suo, J. Cheng, M. Cao, Q. Lu, Y. Yin, J. Xu, and H. Wu, “Assessment of heterogeneity difference between edge and core by using texture analysis: differentiation
of malignant from inflammatory pulmonary nodules and masses,” Academic radiology,
vol. 23, no. 9, pp. 1115–1122, 2016.
[67] I. Tunali, O. Stringfield, A. Guvenis, H. Wang, Y. Liu, Y. Balagurunathan, P. Lambin, R. J. Gillies, and M. B. Schabath, “Radial gradient and radial deviation radiomic
features from pre-surgical ct scans are associated with survival among lung adenocarcinoma patients,” Oncotarget, vol. 8, no. 56, p. 96013, 2017.
[68] O. Grove, A. E. Berglund, M. B. Schabath, H. J. Aerts, A. Dekker, H. Wang, E. R.
Velazquez, P. Lambin, Y. Gu, Y. Balagurunathan et al., “Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity
with prognosis in lung adenocarcinoma,” PloS one, vol. 10, no. 3, p. e0118261, 2015.
[69] J. R. Ferreira, P. M. de Azevedo-Marques, and M. C. Oliveira, “Selecting relevant 3d
image features of margin sharpness and texture for lung nodule retrieval,” International
journal of computer assisted radiology and surgery, vol. 12, no. 3, pp. 509–517, 2017.
[70] G. Lee, H. Park, I. Sohn, S.-H. Lee, S. H. Song, H. Kim, K. S. Lee, Y. M. Shim, and
H. Y. Lee, “Comprehensive computed tomography radiomics analysis of lung adenocarcinoma for prognostication,” The oncologist, vol. 23, no. 7, pp. 806–813, 2018.
[71] N. M. Braman, M. Etesami, P. Prasanna, C. Dubchuk, H. Gilmore, P. Tiwari,
D. Plecha, and A. Madabhushi, “Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy
based on breast dce-mri,” Breast Cancer Research, vol. 19, no. 1, p. 57, 2017.
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invariant texture classification with local binary patterns,” IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 24, no. 7, pp. 971–987, jul 2002.
[104] A. Depeursinge and J. Fageot, “Biomedical texture operators and aggregation functions: A methodological review and user’s guide,” in Biomedical Texture Analysis:
Fundamentals, Applications and Tools, ser. Elsevier-MICCAI Society Book series. Elsevier, 2017, pp. 55–94.
[105] J. Portilla and E. P. Simoncelli, “A Parametric Texture Model Based on Joint Statistics
of Complex Wavelet Coefficients,” International Journal of Computer Vision, vol. 40,
no. 1, pp. 49–70, 2000.
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Appendix B: Intratumoral Heterogeneity Performance

Table B.1: Details of referred papers in Chapter 2.2.1.
Reference Details and Reported Performance
Pre-treatment 18 F-FDG PET imaging was used to predict event-free survival in ER+/HER2- breast cancer patients after neoadjuvant chemotherapy. 143 patients were used in the study. The maximum of standardized
[36]
uptake values (SUVs) showed Hazard Ratio (HR) equal to 3.51 and P-Value
is less than 0.01. For SUVmean HR = 2.76,P-Value = 0.02. For SUVpeak
HR=4.4, P-Value <0.01.
Clinical response to chemotherapy in breast cancer patients was studied
using 18 F-FLT PET data. 53 patients were analyzed. 28 image features
were extracted: including first-order statistics as well as texture features.
All features were studied for their stability first using test-retest methods.
[37]
Area Under a Cumulative SUV-Volume Histogram Curve (AUC-CSH) was
considered a stable feature because of an Intraclass correlation coefficient
larger than 0.7 and AUC-CSH was significantly greater in lesions of responders versus non-responders (P-Value=0.004).
In a 196 breast cancer patient study authors showed that the mean of
ADCmin can be used to differentiate invasive ductal carcinoma (IDC) and
[38]
ductal carcinoma in situ (DCIS) with P-Value¡0.01. The mean ADCmin
value can be used in the differential diagnosis of DCIS, with a cutoff point
of 1.02 x 10/3 mm 2/s (sensitivity of 92.9% and specificity of 57.7%).
Twelve tumors of MCF-7 estradiol (+), 9 tumors of MCF-7 estradiol (-),
and 6 tumors in MDA-MB-231 xenograft models were made. ADC maps
[39]
were created. MCF-7 estradiol (+) showed a higher standard deviation,
maximum, skewness, and kurtosis of ADC values than MCF-7 estradiol (-)
and MDA-MB-231 (P-Value <0.01 for all).
18
F-FES PET images from 46 patients were used for the assessment of the
estrogen receptor analysis. A threshold of SUVmax =1.82 produced sensitiv[40]
ity = 88.2% and specificity = 87.5%. A threshold of SUVmean =1.21 produce
sensitivity = 85.3% and specificity = 93.7%.
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Table B.2: Details of referred papers in Chapter 2.2.2.
Reference Details and Reported Performance
CT images from 150 patients were used for nodal metastasis Spearman’s
Rank (Rs) Correlation evaluation. Normalized standard deviation produced
[41]
a Rs=-0.39, P-Value=0.011. Normalized entropy produced Rs=-0.45, PValue=0.0025. Kurtosis produce Rs=-0.40, P-Value=0.0091.
Entropy and Uniformity features were computed on T1 and T2 MRI images.
Data were collected from 75 breast cancer patients. P-Values of correlation
with Size, Tumor Cellularity, Histologic Grade, Stroma Type, Central Scar,
EIC, Lymphovascular Invasion pathological features were computed. For
[42]
example, the authors showed that Size was correlated with Uniformity and
Entropy in T2 sequence (P-Values 0.015 and 0.008 respectively). At the
same time correlation P-Values between the features in T1 sequence were
0.740 and 0.986 respectively. For more details, please see the paper.
T1 and T2 MRI images were collected from 203 patients with breast cancer.
Feature analysis was performed for recurrence-free survival (RFS) evalua[43]
tion. T1 entropy showed RFS hazard ratio = 4.55; P-Value = 0.018. T2
entropy showed RFS hazard ratio = 9.84; P-Value = 0.001.

Table B.3: Details of referred papers in Chapter 2.2.3.
Reference Details and Reported Performance
Patient treatment outcomes in several cancer types were estimated using
18
F-FDG PET images. Overall, 555 patients diagnosed with breast, cervix,
esophageal, head and neck, and lung cancer were analyzed. Metabolic
[49]
Active Tumor Volume (MATV), as well as Co-occurrence matrix entropy,
showed statistical significance for outcome in Lung Cancer. P-Value=0.0053
for MATV and P-Value=0.002 for the Entropy of the co-occurrence matrix.
Clinical response to chemotherapy in breast cancer patients was studied
using18 F-FLT PET data. 53 patients were analyzed. 28 image features were
extracted: including first-order statistics as well as texture features. All
[37]
features were studied for their stability first using the test-retest method. A
complexity feature from Neighborhood Grey Tone Difference Matrix where
8 and 16 gray levels was used for quantization were statistically significant
treatment response predictor (P-Values = 0.031 and 0.048 respectively).
18
F-FDG PET images of 73 breast cancer patients were used for neoadjuvant
chemotherapy response prediction. Multiple features were used to cluster
[50]
patients into three groups. The authors showed that Pathologic Complete
Response across the clusters was statistically different. 20.0%, 48.0%, and
5.4%. P-Value <0.001.
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Table B.3: (Continued)

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

An ER+/-, HER2+/-, Triple-Negative (TN)+/- breast cancer patient classification system was designed using features of DCE-MRI. 102 patients
were studied. Accuracy of 73.53%, 82.35%, and 77.45% for ER, HER2, and
TN classification was achieved. AUC curves achieved 0.73, 0.84, and 0.83.
36 patients were studied for designing a logistic regression model and training for local recurrence prediction after radiotherapy. CT pre-treatment
images used for texture feature computation. AUC of the model was 0.77.
P-Value=0.0007.
50 non-small cell lung cancer patients and 50 squamous cell esophageal
cancer patients were used for reliability analysis of tumor volume definition.
Tumor volume was defined using multiple modalities and the difference
across modalities was defined. The authors showed that the difference in
tumor volume is correlated with the coefficient of variance (r=0.63) and
entropy (r=0.62).
Contrast-enhanced CT pre-operation images of 148 patients with adenocarcinoma were used for pathological grade classification system development.
Multivariate logistic regression model AUC=0.83.
18
F-FDG PET/CT screening images were used to build a malignancy classification model. Fractal dimension features were computed for 54 patients.
The best diagnostic accuracy reported in the paper was 94.4%.
133 glioblastoma patients were divided into two groups (long/short term
survivals) with respect to patient survival time. T1 MRI images were
used for texture feature extraction. Authors reported the best performance
of SVM model: Sensitivity=0.78%; Specificity=0.79%; Accuracy=0.78%;
AUC=0.80.
The paper is a continuation of [56]. The authors analyzed the model with
usage of texture features extracted from multiple MR sequences. Texture
features were extracted from 126 patients. SVM the best performance
was reported with usage of features from T1 modality: Sensitivity=0.78%;
Specificity=0.83%; Accuracy=0.81%; AUC=0.79.
431 texture features were extracted from 220 patients who had multiparametric MR imaging. The authors built a classification model for low/highgrade gliomas classification (AUC=0.91). The model trained for prediction
of proliferation levels had AUC=0.94.
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Table B.4: Details of referred papers in Chapter 2.2.4.
Reference Details and Reported Performance
Survival time studied using 18 F-FDG PET/CT images of 54 lung cancer
patients. Kaplan-Meier analysis was performed. PET results: Odds ratio
[59]
3.85; 95% confidence limits: 0.9-8.09; P-Value=0.002. CT results: Odds
ratio 56.4; confidence limits: 4.79-666; P-Value=0.001.
Multiparametric MR images from 124 patients were used for designing a
[60]
malignancy evaluation system in breast cancer. The resulting model was
reported to have sensitivity=93%; specificity=85%; AUC=0.91.
Progression free survival (PFS) and overall survival (OS) in 40 glioblastoma
[61]
cases was studied using multiparametric MR imaging. Random forests classifier performed with AUC=85.37% for PFS and AUC=85.54% for OS.
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Table B.5: Details of referred papers in Chapter 2.2.5.
Reference Details and Reported Performance
The authors evaluate the robustness of developed features in multiple experiments using several datasets. Classification of radiation necrosis (RN)
from recurrent brain tumors (RBT) on T1 MRI in 42 brain tumors patients;
triple-negative (TN), ER+, HER2+, fibtoadenomas (FA) breast cancer subtypes classification on DCE-MRI images of 65 patients; Differentiation of
adenocarcinoma tumors from granulomas nodules on 120 CT studies. The
[62]
authors performed 150 iterations of 3-fold-cross-validation using a Random
Forests classifier. Reported results (Accuracy %): RN vs RBT (GBM)
83.73±5.43; RN vs RBT (Metastatic) 88.52±3.93; TN vs ER+ 72.53±5.19;
TN vs HER2+ 71.64±6.13; TN vs FA 90.06±4.38; Adenocarcinoma vs
Granuloma (Training) 70.9±7.1; Adenocarcinoma vs Granuloma (Testing)
69.8.
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Appendix C: Peritumoral Heterogeneity Performance

Table C.1: Details of referred papers in Chapter 2.3.
Reference Details and Reported Performance
Overall survival (OS) of 108 adenocarcinoma patients were analyzed using
pre-surgical CT images. The two newly designed features that were found
to be associated with OS after adjusting for clinical covariates were radial
[67]
deviation outside-border separation (HR = 0.24; 95% CI 0.10-0.58, p =
0.001) and radial gradient outside-tumor separation mean (HR = 0.31; 95%
CI0.13- 0.72, p = 0.006).
Two developed features extracted from CT images were associated with
Overall Survival (OS) in 108 Adenocarcinoma patients. A shape fea[68]
ture (Convexity) was a statistically significant biomarker of OS with PValue=0.008 as well as texture feature (Entropy Ratio) with P-Value=0.04.
The authors extracted 48 features from the LIDC dataset and presented
evaluation methods for space reduction (feature selection) in a tumor re[69]
trieval task. The authors reported feature reduction of 83% while achieving
up-to-dates methods performance.
Pre-surgery CT images from 339 adenocarcinoma patients were analyzed for
overall survival (OS). 161 radiomic features were extracted as well as de[70]
mographic and pathological features. A combination of clinicopathological
and radiomic features produced a C-Index = 0.772 and 95% CI 0.694-0.85.
48 contrast-enhanced CT nodule images were used for diagnostic model
design. Mean attenuation value (AV) and entropy features for core and
[66]
edge regions of a nodule were extracted. AUC of the AV feature was 0.84
and for the entropy feature was 0.79. The combination of features produced
AUC=0.86.
117 breast cancer patients had DCE-MR pre-treatment (chemotherapy)
imaging. The resulting data was used for designing a pathological com[71]
plete response (pCR) prediction model design. Among all pathology group
patients, AUC in the test set was 0.74 using diagonal linear discriminant
analysis.
DCE-MR images from 84 patients with breast cancer were used to build
[65]
an SVM model trained to identify triple-negative tumors. Cross-Validation
was performed. The reported AUC of the final model was 0.88.
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Table C.1: (Continued)
[64]

Peritumoral edema analyzed in pre-surgery MRI to discriminate glioblastoma from single brain metastasis in 43 patients. The authors reported
sensitivity 80% and specificity 90%.
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Appendix D: Spatial Heterogeneity Performance

Table D.1: Details of referred papers in Chapter 2.4.1.
Reference Details and Reported Performance
32 glioblastoma patients from TCGA with T1 and T2 MR images were used
[73]
to build a short/long term patient survival classification model. Leave-oneout and 10-fold cross-validation showed an accuracy = 81.25%.
Two datasets with 32 (A) and 22 (B) glioblastoma patients with multipametric MR images were used to build short/long term patient survival classi[74]
fication model. Leave-one-out cross-validation showed an accuracy=87.50%
for dataset A and accuracy=86.36% for dataset B.
Multiparametric MRI’s from 85 glioblastoma patients located at TCGA
were used to detect 16 habitats. Using Cox proportional hazards regression
[75]
analysis authors showed that 3 revealed habitats are statistically correlated
with patient survival time.
12-month survival status and EGFR classification models were designed
using 65 glioblastoma patients with T1 and T2 MRI. The survival sta[76]
tus model produced AUC=0.74; sensitivity=0.59%; specificity=0.75%. The
EGFR classification model produced accuracy=0.85; sensitivity=0.76%;
specificity=0.83%.
12-month survival status classification models were designed using 74
glioblastoma patients with multiparametric MRI. A survival status
[77]
model produced AUC=0.76; accuracy=0.75%; sensitivity=0.86%; specificity=0.64%.

Table D.2: Details of referred papers in Chapter 2.4.2.
Reference Details and Reported Performance
60 patients with triple-negative early-stage cancer received neoadjuvant
chemotherapy. Dynamic Contrast-Enhanced MR images were used to build
[78]
a treatment response model. A pathological complete response prediction
model was reported to have AUC=0.68. A residual tumor with lymph node
metastases prediction model had an AUC=0.83.
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Table D.2: (Continued)

[79]

[80]

An estrogen receptors status classification model in breast cancer was
presented using 20 patients with dynamic contrast-enhanced MR images.
Naive Bayes classifier with leave-one-out cross-validation produced an accuracy=85%.
Recurrence-free survival analysis in 246 breast cancer patients was performed using Dynamic Contrast-Enhanced MR images. Reported Hazard
ratio=3.42; 95% CI 1.55-7.57; P-Value was 0.002.

Table D.3: Details of referred papers in Chapter 2.4.3.
Reference Details and Reported Performance
A metastasis prediction model in soft tissue sarcoma was designed based on
[81]
multiparametric MR images. The total number of analyzed patients was
87. The reported accuracy was 76.22%.
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